Study Title: 
Sponsor: 
INDNumber: 
EudraCT Number: 
Clinical Trials.gov 
Identifier: 
Indication: 
Protocol ID: ~ GILEAU 
CLINICAL STUDY PROTOCOL 
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 
Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy 
of GS-[ADDRESS_867471] 
Foster City, CA [ZIP_CODE] 
IND 123903 
2016-001496-75 
TBD 
Rheumatoid Arthritis 
GS-US-379-1582 
[COMPANY_009] Clinical Name: [CONTACT_647815]: Telephone: 
Fax: 
[COMPANY_009] Medical Name: 
[CONTACT_580889]: Telephone: 
Fax: 
Mobile: 
Protocol Version/Date: Original: Franziska Matzkies 
[COMPANY_003] [COMPANY_003] 
[COMPANY_003] 
[ADDRESS_867472] OF IN- TEXT FIGURES ...................................................................................................................................... 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 11
1.INTRODUCTION .............................................................................................................................................. 15
1.1.Background ............................................................................................................................................ 15
1.2.GS-9876................................................................................................................................................. 15
1.2.1. General Information ............................................................................................................. 15
1.2.2. Preclinical Pharmacology and Toxicology ........................................................................... 15
1.2.3. Clinical Trials of GS -9876................................................................................................... 19
1.3.Information about Methotrexate ............................................................................................................. 20
1.4.Rationale for Current Study ................................................................................................................... 20
1.5.Rationale for Dose Selection .................................................................................................................. 21
1.6.Risk/Benefit Assessment for the Study .................................................................................................. [ADDRESS_867473] Study Care ...................................................................................................................................... 27
3.8.Pharmacokinetic (PK) Assessments ....................................................................................................... [ADDRESS_867474] Selection ............................................................................................ 29
4.2.Inclusion Criteria .................................................................................................................................... 29
4.3.Exclusion Criteria ................................................................................................................................... 30
5.INVESTIGATIONAL MEDI CINAL PRODUCTS........................................................................................... 33
5.1.Randomization, Blinding and Treatment Codes .................................................................................... 33
5.1.1. Procedures for Breaking Treatment Codes ........................................................................... 33
5.2.Description and Handling of GS -9876 and Placebo -To-Match (PTM) GS -9876.................................. [ADDRESS_867475] Enrollment and Treatment Assignment ..................................................................................... 39
6.2.Pretreatment Assessments ...................................................................................................................... 39
6.2.1. Screening Visit (within 28 days prior to randomization) ..................................................... 39
6.3.Randomization (Day 1) ...............................................................
........................................................... 41
6.4.Treatment Assessments .......................................................................................................................... 41
6.4.1. Day 1.................................................................................................................................... 41
6.4.2. Week 2 (+ 3 days) ................................................................................................................ 42
6.4.3. Week 4 (+ 3 days) ................................................................................................................ 43
6.4.4. Week 8 (+ 3 days) ................................................................................................................ 44
6.4.5. Week 12 (+ 3 days) .............................................................................................................. 45
6.5.Early Termination (+ 3 days) ................................................................................................................. [ADDRESS_867476]-Treatment Assessments (+ 5 days) ................................................................................................
.47
6.7.Sample Storage ....................................................................................................................................... 48
7.ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 49
7.1.Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events ................................. 49
7.1.1. Adverse Events ..................................................................................................................... 49
7.1.2. Serious Adverse Events ........................................................................................................ 49
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events ...............................................................
..........50
7.2.Assessment of Adverse Events and Serious Adverse Events ................................................................. 50
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 50
7.2.2. Assessment of Severity ................................................................
........................................ 51
7.3.Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to [COMPANY_009] ....................................................................................................................... 51
7.3.1. Requirements for collection prior to study drug initiation: .................................................. [ADDRESS_867477] (IRB)/Independent Ethics Committee (IEC) 
Review and Approval ........................................................................................................... [ADDRESS_867478] Accountability and Return ............................................. 66
9.1.8. Inspections ............................................................................................................................ 66
9.1.9. Protocol Compliance ............................................................................................................ 67
9.2.Sponsor Responsibilities ................................
........................................................................................ 67
9.2.1. Protocol Modifications ......................................................................................................... 67
9.2.2. Study Report and Publications ............................................................................................. 67
9.3.Joint Investigator/Sponsor Responsibilities ........................................................................................... 67
9.3.1. Payment Reporting ............................................................................................................... 67
9.3.2. Access to Information for Monitoring .................................................................................. 68
9.3.3. Access to Information for Auditing or Inspections .............................................................. 68
9.3.4. Study Discontin uation.......................................................................................................... 68
10.REFERENCES ................................................................................................................................................... 69
11.APPENDICES .................................................................................................................................................... 71
Appendix 1.Investigator Signature [CONTACT_3490] .................................................................................................... 72
Appendix 2.Study Procedures Tables ........................................................................................................ 73
Appendix 3.Laboratory Assessments Table ............................................................................................... 76
Appendix 4.Common Terminology Criteria for Adverse Events (CTCAE) v4.03 .................................... 77
Appendix 5.Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................... 78
Appendix 6.The 2010 American College of Rheumatology –European League Aga inst 
Rheumatism Collaborative Initiative Classification Criteria for Rheumatoid 
Arthritis {Aletaha et al 2010} ................................................................................................. 80
Appendix 7.American College of Rheumatology Response Evaluations/ Preliminary Definition 
of Improvement in R heumatoid Arthritis {Felson et al 1995} ............................................... 82
Appendix 8.Disease Activity Score for 28 Joint Count (DAS28) {Prevoo et al 1995} ............................. [ADDRESS_867479] OF IN -TEXT TABLES
Table1-1. Margins for GS -9876 Based on Systemic Exposure Relative to the Observed 
Human Exposure at 30 mg once daily (AUC) ...............................................................
.........[ADDRESS_867480] OF IN -TEXT FIGURES
Figure3-1.Study Schema ......................................................................................................................... 25
GS-9876 
Protocol GS-US-379-1582 
[COMPANY_009] Sciences, Inc. 
Study Title: 
INDNumber: 
EudraCT Number: 
Clinical Trials.gov 
Identifier: 
Study Centers 
Planned: 
Objectives: 
CONFIDENTIAL PROTOCOL SYNOPSIS 
[COMPANY_009] Sciences, Inc. 
[ADDRESS_867481] 
Foster City, CA [ZIP_CODE] Original 
A Randomized, Double-Blind , Placebo-Controlled, Multicenter, 
Proof-of-Concept Study to Evaluate Safety, Tolerability, and 
Efficacy of GS-9876 in Subjects with Active Rheumatoid Arthritis 
on Backgrmmd Therapy with Methotrexate 
IND 123903 
Not Available 
Not Available 
Approximately 30-40 centers globally 
The primaty objective of this study is as follows: 
• To evaluate the effect ofGS-9876 versus placebo for the 
treatment of signs and symptoms of rheumatoid atihritis (RA) in 
subjects with active RA as measmed by [CONTACT_647798] 28 joint count using C-reactive protein 
(CRP) (DAS28 [CRP]) at Week 12 
The secondaty objective of this study is as follows: 
• To evaluate the safety and tolerability of GS-9876 in subjects 
withRA 
• To explore the effect of GS-9876 on other disease-specific 
outcomes in RA 
The explorat01y objectives of this study are: 
I 
I 
Page 6 08 April2016 
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page7 08 April2016Study Design: This is a randomized, double -blind, placebo -controlled, 
proof-of-concept(POC)study 
evaluating the safety , tolerability , and 
efficacy of GS-9876 in adult male and female subjects with active 
RA despi[INVESTIGATOR_40953] y who had an inadequate response to MTX 
(either alone orin combination with biological disease modify ing 
anti-rheumatic drug [
bDMARDs]) .
Approximately 60 subjects will be randomized in a 1
:1:1 ratio to 
receive 30 mg GS -9876, 10 mg GS
-9876 or placebo- to-match (PTM) 
in addition to background therap y with MTX for up to 12 weeks:
GS-9876 (30 mg QD) (N=20)
GS-9876 (10 mg QD) (N=20)
GS-9876 PTM (QD) (N=20)
Randomization will be stratified b y prior inadequate response to 
biologic therap y and geographic region.  
Subjects will be followed for [ADDRESS_867482] dose of study  
drug. 
Number of Subjects 
Planned:Approximately  60 subjects
Target Population: Subjects with active RA on background MTX therapy who had an 
inadequate response to MTX (either aloneorin combination with
bDMARDs ). 
Duration of 
Treatment:Up to12 weeks
Diagnosis and Main 
Eligibility  Criteria:Male or non- pregnant female subjects with active RA, between 
18and 75 yearsof age (inclusive)
Key Inclusion Criteria include:
1)Active 
RA disease as defined by : a tender joint count (TJC) of
≥6 (out of 68) ,a swollen joint count (SJC) of ≥6 (out of 66) ,
anda CRP ≥ 5 mg/l
2)Inadequate response  to treatment with oral or parenteral MTX 
7.5 to 25 mg/week continuously  for at least [ADDRESS_867483] dose of study  drug
3)Subjects must be receiving a folic or folinic acid supplementation 
at a stable dose. Subjects who are not taki ng folic or folinic acid 
at Screening, should be initiatedon an adequate dose of folic acid 
(≥5 mg/week total dose or as per local prac tice) or equivalent and 
maintained throughout the study .
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page8 08 April20164)Use of oral corticosteroids of no more than [ADDRESS_867484] dose of study  drug 
5)Nonsteroidal Anti -inflammatory  Drugs(NSAIDs) or other 
analgesics (includin g aspi[INVESTIGATOR_248] 
≤ 100 mg dail y) are allowed if doses 
are stable for at least [ADDRESS_867485] dose of study  drug  
Key Exclusion Criteria include:
1) Prior treatment with B-cell depleting agents ( eg, rituximab) , 
unless more than 6 months prior and documented return of 
CD19+cells
2)Prior treatment with an y commerciall y available or 
investigational SYKinhibitor 
3)Current treatment with any  otherconventional DMARD 
(cDMARD) other than MTX and/or hy droxychloroquine (HCQ) 
(unless appropriate wash out as d efined in Section 5.5)
4)Current treatment with any  bDMARD (unless appropriate wash 
out as defined in Section 5.5)
5)QT interval corrected for heart rate using the Fredericia formula 
(QTcF) > 450 msec determined b y the average of values at the 
Screening visit
6)History of any major bleeding event defined as Grade 3 severit y 
and above [as defined b y modified the Common Terminology  
Criteria for Adverse Events (CTCAE) 4.03] within the last y ear
or personal or family  history of bleeding disorder
7)If no history  of a documented negative tuberculosis (TB) test 
within the last [ADDRESS_867486] be 
performed according to local standards. Subjects with a positive 
Quantiferon at Screening are not eligible
8)Ongoing treatment with moderate or strong CYP3A inducers or 
inhibitors or within [ADDRESS_867487] Population.
Study Procedures/
Frequency :All subjects will complete the following stud y visits: Screening, 
Day1 (first dose), and on -treatment visits at Weeks 2, 4, 8, and 12.  
All subjects will be followed for safet y for an additional [ADDRESS_867488] dose of study  drug. 
Screening assessments will be completed no more than 28 day s prior 
to the Day  1 visit and will include a complete ph ysical examination
(PE), joint count assessment, medical history , vital signs, height and 
weight, electrocardiogram (ECG), adverse events ( AEs)related to 
GS-[ADDRESS_867489], Dose, 
and Mode of 
Administration: 
Reference Therapy, 
Dose, and Mode of 
Administration 
Required Background 
therapy 
Criteria for 
Evaluation: 
Safety: 
CONFIDENTIAL Original 
screening procedures , concomitant medications , safety laboratmy 
tests (including hematology , chemistiy , and coagulation), CRP, 
serology (HIV, HCV, HBV), leukocyte subsets, biomarkers, RNA, 
TB test as applicable and as outlined in the protocol, urinalysis , urine 
dmg screen, and CD19 count as applicable and as outlined in the 
protocol. Pregnancy testing will be perfmmed for females of 
childbearing potential. 
On-ti·eatment assessments include a symptom driven PE, joint count 
assessment , disease-specific questionnaires and activity scales, vital 
signs, ECGs, AEs, concomitant medications , safety laboratmy tests 
(including hematology , chemistiy , and coagulation), leukocyte 
subsets (Day 1 and Week 12 ), quantitative imnllmoglobulins (Day 1 
and Week 12 or ET), RNA (Day 1, Week 4, and Week 12 or ET), 
RF/CCP [Day 1 and Week 12 or ET], CRP, urine pregnancy test, and 
biomarkers (Day 1, Week 4, and Week 12 or ET). Additiona l testing 
will include PK sampling (Day 1, Weeks 2, 4, 8 and 12 or ET). 
Post-treatment assessments include symptom driven PE, vital signs, 
ECGs, AEs, concomitant medications, safety laborato1y tests 
(including hematology , chemistly , and coagulation), CRP, and urine 
pregnancy test where indicated. 
For sub'ects who provide their additional and s ecific consent, 
[COMPANY_003] 
For subjects who provide their additional and specific consent, PO 
GS-9876 30 mg (1 x 30 mg tablet), administered orally once daily 
GS-9876 10 mg (1 x 10 mg tablet), administered orally once daily 
GS-9876 PTM (1 tablet), administered orally once daily 
MTX 7.5 to 25 mg, administered orally or parenterally once a week 
Safety will be assessed through the repmting of AEs, clinical 
laboratmy tests, PEs, vital sign assessments, and ECGs at various 
time points during the study. Concomitant medication usage will 
also be documented throughout the study. 
Page 9 08 April2016 
GS-9876 
Protocol GS-US-379-1582 
[COMPANY_009] Sciences, Inc. 
Efficacy: 
Phru.macokinetics: 
Exploratoty: 
Statistical Methods: Original 
The primru.y endpoint is change from baseline in DAS28 (CRP) at 
Week 12. 
The secondru.y endpoints include: 
• The propottion of subjects who achieve ACR 20/50/70 at 
Week 12 
• Change from baseline in Heath Assessment 
Questionnaire- Disability Index (HAQ-DI) score at Week 12 
Plasma concentrations ofGS-9876 will be detetmined. 
[COMPANY_003] 
The primmy endpoint is change from baseline in DAS28 (CRP) at 
Week 12. The primmy analysis will consist of a superiority test of 
each of the GS-9876 doses compared to placebo based on the change 
from baseline in DAS28 (CRP) at Week 12. 
All continuous endpoints will be summm·ized using an 8-number 
summaty [n, mean, standard deviation (SD), median, 1st quartile 
(Ql), 3rd quattile (Q3), minimum , maximum] by [CONTACT_1570]. 
All categorical endpoints will be summm·ized by [CONTACT_204953]. 
Safety endpoints will be analyzed by [CONTACT_647799] 
8-number Slllllllla.J.Y (n, mean, SD, medim1, Ql, Q3, minimum, 
maximum) for continuous data by [CONTACT_647800]'eatment group. 
Sample size is detetmined based on the superiority test of one dose of 
GS-9876 compared to placebo based on the change from baseline in 
DAS28 (CRP) at Week 12. When assuming a difference of 
1.[ADDRESS_867490] deviation of 
1.35, 20 subjects in each of the GS-9876 groups and 20 in the 
placebo group are required to obtain 78% power at a 2-sided 
0.05-level. Therefore, the total sample size will be 60 (20 per 
treatment group). 
This study will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents. 
CONFIDENTIAL Page 10 08 April2016 
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page11 08 April2016GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
°C degrees Celsius
°
F degrees Fahrenheit 
β-hCG beta-human chorionic gonadotropin
μM micromolar
ACPA anti-citrullinated protein antibody
ACR American College of Rheumatology
ACR 20/50/70 American College of Rheumatology 20/50/70%  improvement
ADP adenosine di -phosphate
AE adverse event
AhR aryl hydrocarbon receptor
AKT protein kinase B
ALT alanine aminotransferase
APC antigen-presenting cell
APTT activated partial thromboplastin time
AST aspartate aminotransferase
ATP adenosine triphosphate
AUC area under the curve
AUC0-last area under the plasma/serum concentration versus time curve from time zero to 
the last quantifiable concentration
BCR B-cell receptor
BCRP breast cancer resistance protein
BDC bile duct-cannulated
bDMARD biological disease modifying anti -rheumatic drug
BLNK B-cell linker protein
BLQ below the limit of quantitation
BTK Bruton’s tyrosine kinase
BUN blood urea nitrogen
CBC complete blood count
CCP cyclic citrullinated peptide
CDAI Clinical Disease Activity Index
CFR Code of Federal Regulations
CG Cockcroft -Gault
CIA collagen-induced arthritis 
Cmax the maximum observed serum/plasma/peripheral blood mononuclear cell 
concentration of drug
CMH Cochran–Mantel–Haenszel
CNS central nervous system
CRO contract research organization
CRP C
-reactive protein
GS-[ADDRESS_867491] disease modifying anti -rheumatic drug
DMC Data Monitoring Committee
DSPH Drug Safety and Public Health
EC50 estimated concentration of drug for a half maximal response
ECG electrocardiogram
eCRF electronic case report form
EDC electronic data capture
ERK extracellular signal -regulated kinase
eSAE electronic serious adverse event
ESR erythrocyte sedimentation rate
ET early termination
EU European Union
FAS Full Analysis Set
FDA ([LOCATION_002]) Food and Drug Administration
g gram
GCP Good Clinical Practice
[COMPANY_009] [COMPANY_009] Sciences, Inc.
GLP Good Laboratory Practice
HAQ-DI Health Assessment Questionnaire –Disability Index
HBV hepatitis B virus
HCQ hydroxychloroquine
HCV hepatitis C virus
HDPE high density polyethylene
hERG human ether -a-go-go-related gene
HIV human immunodeficiency virus
HLGT high-level group term
HLT high-level term
IB Investigator’s Brochure 
IC immune complex
IC50 concentration that results in 50% inhibition
ICH International Conference on Harmonization 
ICH E3 ICH Guideline for Structure and Content of Clinical Study Reports
ie id est (that is)
IEC Independent Ethics Committee
Ig immunoglobulin
IL interleukin
IMP investigational medicinal product
GS-[ADDRESS_867492]
IU international units
IUD intrauterine device
IXRS Interactive Web and Mobile Response System
kg kilogram
L liter
LAM lactational amenorrhea method
LLT lower-level term
MAPK mitogen-activated protein kinase
MCV mean corpuscular volume 
MedDRA Medical Dictionary for Regulatory Activities
MEK MAPK/ERK kinase
mg milligram
MMRM mixed model repeated measures
msec millisecond
MTX methotrexate
ng nanogram
nM nanomolar
NOEAL no-observed-adverse-effect-level 
NSAID nonsteroidal anti -inflammatory drug
OATP organic anion transporting polypeptide
PAR-
1 protease-activated receptor
PD pharmacodynamics
PE physical examination
P-gp P-glycoprotein
PK pharmacokinetics
PKC protein kinase C
POC proof-of-concept
prn pro re nata (as needed)
PT preferred term or prothrombin time
PTM placebo-to-match
PTT partial thromboplastin time
PXR pregnane X receptor
Q1 first quartile
Q3 third quartile
QD quaque die (each day)
GS-[ADDRESS_867493] upper limit of normal
US, [LOCATION_003] [LOCATION_002], [LOCATION_002] of America
VAS visual analog scale
WBC white blood cell
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page15 08 April20161. INTRODUCTION
1.1. Background
Rheumatoid Arthritis is a chronic, s ystemic inflammatory disease that affects approximately  
1.3
million adults in the [LOCATION_002] ( US) {Helmick et al 2008 }. RA manifests principally  as 
an attack on peripheral joints and may  lead to marked destruction and deformity  of joints, with 
considerable disabilit y and impact on quality of life. I t is characterized by  [CONTACT_454168], sy novial inflammation with formation of pannus tissue, and erosion of 
underlying cartilage and bone. Although people of any  age can be affected, the onset of RAis 
most frequent between the age of [ADDRESS_867494] been implicated in 
itspathogenesis. Patients with RA experience a high ri sk of disabilit yand mortality  {
Arthritis 
Foundation 2008 }.
Despi[INVESTIGATOR_279364] y available treatment options for RA, there is still a need for new treatments 
because not all patients respond adequately (or maintain response) to current therapi[INVESTIGATOR_647787]/or intolerance that limit the use of such therapi[INVESTIGATOR_014]. All currently 
available treatments have safet y considerations that can develop during chronic use that may  
require a change to a different therap y. The unmet medical need for new therapeutic options with 
a favorable efficacy  and safet y profile that do not requ ire injection/infusion have prompted 
efforts to develop oral small molecule inhibitors of protein kinases involved in cellular signaling 
associated with theunderlying RA disease pathology . 
G
S-9876 is a potent and selective inhibitor of SYKand is being d eveloped b y [COMPANY_009] Sciences, 
Inc. ([COMPANY_009]) as an oral agent for the treatment of inflammatory  diseases. Spleen ty rosine kinase 
is a nonreceptor cy toplasmic ty rosine kinase primarily  expressed in cells of hematopoietic 
lineage, where it functions as a key  signaling molecule mediating immunoreceptor signaling in a 
range of cells involved in inflammatory  disease. Given its central role in immune cell signaling, 
inhibition of SYKis expected to affect multiple steps in the pathogenesis of RA resulting in 
pleiotropic anti -inflammatory  effects.
1.2. GS-9876
1.2.1. General Information
For further information on GS-
9876, refer to the current Investigator’s Brochure (IB).
1.2.2. Preclinical Pharmacology and Toxicology
[IP_ADDRESS]. Preclinical Pharmacology and Safet y Pharmacology
In biochemical assay s, GS-[ADDRESS_867495] 7 -fold more selective biochemically  for 
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page16 08 April2016SYKrelative to all other protein kinases assay ed. The potency  of GS-9876 to inhibit SYK
activation was also assessed in human and rat whole blood. L evels of autophosphory lation and 
activation of SYKon tyrosines (Y) 525/6 in blood samples preincubated with GS- 9876 showed 
potent inhibition of 
phosphoSYK-Y525/6 levels in human and rat whole blood with EC 50values 
of 171 nM and 230 nM, respecitivel y. Studies with human whole blood also showed that 
GS-9876 inhibited anti-IgD/BCR-induced CD69 expression on B -cells (geometric mean 
EC50=301 nM) and anti-FceRI-stimulated CD63 expression on basophils (geometric mean 
EC50= 73.2 nM in 25% human blood and 221.8 nM in 67% blood).
The ability  of GS-9876 to inhibit SYKsignaling in primary  human B -cells, lymphocytes,and 
macrophages was assessed in vitro . GS-9876 inhibited anti- IgM-induced BCR/ SYK-mediated 
phosphory lation and activation of multiple downstream signaling pathway s in primary  human 
B-cells including AKT, BLNK, BTK, ERK, MEK, and PKC with EC 50values ranging from 
24 to 51 nM. GS- 9876 also suppres sed anti-IgM-inducedCD69 and CD86 expression on human 
peripheral blood B- cells with EC 50values of 112 nM and 164 nM, respectively . BCR and 
CD40costimulation of B -cell proliferation and anti-CD3/anti-CD28 costimulation of T -cell 
proliferation was also in hibited by  [CONTACT_10827]-9876 with EC50values of 108 nM and 1291 nM, 
respectivel y, demonstrating a 12 -fold relative functional selectivity  of GS-9876 for B -cells 
compared to T -cells. In immune complex ( IC)-stimulated cy tokine release assay sin primary  
human monocy tedifferentiated macrophages, GS -9876 inhibited I C-stimulated TNF-α, IL-1, and 
IL-6 secretion with geometric mean EC 50values of 121 nM, 93 nM, and 909 nM, respectivel y, 
demonstrating that GS -9876 inhibition of SYK blocks B-cell and macrophage receptor sign aling 
in vitro with similar potencies.
In two independent rat collagen -induced arthritis (CI A) model s in animals with established 
disease, treatment with GS -9876 caused significant and dose -dependent amelioration of clinical 
and histopathology  parameters w hen dosed either earl y (at initiation of ankle swelling) or late ( at 
time of peak ankle swelling) afterdisease onset . Histological evaluation of joints in the animals 
from the study  demonstrated that GS- 9876 treatment reduced pannus formation, cartilage 
damage, bone resorption, and periosteal bone formation with an effective dose inducing a 
50%inhibitory  effect (ED 50) of < 6.25 mg/kg, QD and 11.6 mg/kg, QD in the earl y and late CIA 
models, respectivel y.  Significant efficacy  was seen with GS -9876 doses that produced 
Caveexposures that were calculated to inhibit Sy k phosphory lation by 50% (EC 50).  GS-9876 was 
well tolerated at all doses andthere were no treatment
-related adverse effects on body  weight, 
food and drink intake, in -life observations or clin ical pathology  parameters.  
Safety pharmacology  studies were conducted to examine the potential effects of GS
-9876 on the
cardiovascular , respi[INVESTIGATOR_696] , and CNS sy stems. There were no clinically -relevant effects on the 
respi[INVESTIGATOR_696] ,and CNS sy stems after sin gle oral doses up to 300 mg/kg. C ardiovascular effects in 
telemetered cy nomolgus monkeys at ≥ 20 mg/kg included prolonged QTc interval from 
5through 25 hours postdose, slightly higher systolic, diastolic, and mean arterial pressure with 
lower heart rate t hrough6 hours postdose, and higher heart rate from 9 through 25 hours 
postdose. While differences in QTc interval were generally small, the changes were of sufficient 
magnitude to be considered biologically  relevant.There were no inhibitory  effects on the hERG 
potassium current when GS -9876 was tested up to a free drug concentration of 30 μM, 
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page17 08 April2016approximately  207-fold above the observed stead y state C maxat a 30mg QD clinical dose. 
Further, no cardiovascular effects were observed in telemetered cy nomolgus m onkeys 
administered GS -9876 for 13 weeks at doses up to 15 mg/kg/day . The potential for GS -9876 to 
prolong the QTc interval was assessed with intensive time matched ECG monitoring in [COMPANY_009] 
studies GS- US-379-1372 and GS -US-
379-1900 (cohorts 1 and 2), and no clinical significant 
change in time matched QTc intervals was observed. No clinical significant changes in vital 
signs during serial vital sign measurements wereobserved.
[IP_ADDRESS]. Preclinical Toxicology
In the repe at-dose studies, the toxicity  profile of GS -9876 was assessed in rats and monkey s 
administered GS -9876 orally  for up to 26 weeks. Dose-dependent effects on ly mphocytes in both 
rats and monkey s were consistent with the expected pharmacology  of SYK inhibitio n. Effects on 
hemostasis were observed in rats and monkey s, with increased ery throcyte turnover in rats at 
≥ 10mg/kg/day , and hemorrhage and thrombosis in monkey s at ≥ 20mg/kg/day. At higher doses 
in rats (≥ 30mg/kg/day ), mortality  associated with bacte rial infections, likely  resulting from the 
immunomodulatory  activity of GS-9876, was seen. Additional findings included ly mphoid 
depletion in the thy mus, changes in the pancreas, with secondary  effects related to the 
immunomodulatory  activity of GS-9876, and likely opportunistic bacterial infection, observed in 
several tissues. The no-observed-adverse- effect level (NOAEL) in rats was 10 mg/kg/day  after 
[ADDRESS_867496] proposed dose 30mg dose, estimated exposure margins are 
2.4-/5.9-fold based on exposures at the NOAELs in the 26 week study  in male/female rats.  
Patients will be closely  monitored for any  infection andchanges in the differential CBC.
In monkey s, the NOAEL in the 28- day study was identified at 10 mg/kg/day , which was 
associated with AUC 0-24hrof 4290 ng •hr/mL. In the 13- week monkey  study, there were no effects 
on hemostasis, and the NOAEL was the high dose of 15mg/kg/day . However in the ongoing 
39-week stud y, one 15 mg/kg/day monkey was euthanized moribund during Week [ADDRESS_867497] proposed dose 30mg dose, the estimated exposure margin is 2.7-fold based on 
exposures at the 15 mg/kg/day  NOAEL in the 13- week monkey study.Although the relationship 
of the moribund animal to GS -9876 treatment is uncertain, [COMPANY_009] considers it prudent to limit 
exposures to mean exposures achieved in monkeys at the 10mg/kg/day  mid-dose at Week 13 of 
the 39-week stud y (6750ng.h/mL), whichwere 1.8-fold above estimated exposure s at the 
highest proposed dose 30mg dose.
In GLP range-finding developmental toxicity  studies in pregnant rats and rabbits, n o 
Caesarean- sectioning, litter parameters, or gross external or visceral alterations were affected by  
[CONTACT_10827]-9876 at dose levels up to 100 mg/kg/day in rats, or up to 30 mg/kg/day  in rabbits. In rabbits 
at 100mg/kg/day , mortality , clinical observations, reduced bod y weightsand food consumption
in does were associated with increased resorptions and reduced fetal body  weights.  In rats, t he 
maternal no -observed- effect level (NOEL) was 30 mg/kg/day , and theembryo-fetal development 
NOEL was 100 mg/kg/day. In rabbits, the m aternal and embry o-fetal development NOEL was 
30 mg/kg/day .
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page18 08 April2016GS-9876 was negative in the bacterial reverse mutation (Ames) assay , in vitro chromosomal
aberration assay , and in vivo rat micronucleus assay and is therefore considered to be
nongenotoxic. In th e in vitro chromosome aberration assay  in human ly mphocytes, slight, but
statistically  significant increases in the number of poly ploid cells was observed at the highest
GS-9876 dose level evaluated. GS -9876 did not induce structural chromosome breakage wh en
evaluated in the in vitro assay . 
Table1-
1. Margins for GS -9876 Based on Systemic Exposure Relative to the 
Observed Human Exposure at 30 mgonce daily (AUC)
Species Duration RouteNOAEL
(mg/kg/day)AUC0-24
(
ng
•h/mL)aMarginb
Rat Oncedaily 
x26weeksOral 10 8800/21 ,800
(male/female)2.4/5.9
(male/female)
Cynomolgus Monkey Once daily 
x13weeksOral 15c10,[ADDRESS_867498] level. Week 4 male and female rat AUC and week 13Cynomolgus monkey AUC
(combined sex)
bMargins of exposure were calculated using observed steady -stateexposure (AUC tau) in humans of 3708 ng•h/mL at 30 mg 
oncedailyin study GS -US-379-1900.
c One animal was euthanized moribund during Week 22 at the 15 mg/kg/day dose level.
[IP_ADDRESS]. Preclinical Drug Metabolism and Pharmacokinetics
Consistent with the high absorption observed in nonclinical species, GS -9876 shows high
permeability  and low efflux transport across human Caco -2 cell monolay ers. Efflux is likely
mediated b yP-gp and BCRP.
The whole blood to plasma ratios determined in rats, dogs, cy nomolgus and rhesus monkey s, and
humans ranged from 0.83 in rats to 2.38 in cy nomolgus monkey s. GS-9876 plasma protein
binding at 2 μM is moderate in all species with the free fra ction ranging from 11.8% in rat to 
38.5% in dog. In human plasma, GS- 9876 has an average free fraction of 20.4%.
The oral bioavailability  of GS-9876 is high in rat, dog, and cy nomolgus monkey  and is
independent of the formulation used (F ≥ 60%). GS -9876 had low to intermediate clearance
relative to liver blood flow in rats, dogs, and cy nomolgus and rhesus monkey s. Across species,
the in vivo clearance is similar to the predicted hepatic clearance obtained in primary  hepatocy tes
leading to confidence in the human prediction based on in vitro hepatocy te data. The volume of
distribution is approximately equal to (rat) or higher than (all other species) total body  water
(0.7L/kg).
After oral dosing to albino and pi[INVESTIGATOR_14922], [14C]GS-9876-derived radioactivit y was
distributed to most of the tissues by  [CONTACT_647801] (0.25 hours postdose). Most
tissues reached maximum GS -[ADDRESS_867499] levels of radioactivity  were observed in the brain, bone, adipose, and testis. Generall y
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page19 08 April2016similar distribution patterns a nd tissue concentrations of [14C]GS-9876-derived radioactivity
were observed in albino and pi[INVESTIGATOR_647788] e uveal tract
where higher tissue/blood ratios were seen in melanin- containing tissues. Binding was reversible.
Inboth strains, the brain/blood concentration ratio was low (< 0.1), suggesting
[14C]GS-9876-derived radioactivity  was relativel y excluded by  [CONTACT_33428]:brain barrier.
Recovery  of radioactivity dosed orall y to rats was high ( ≥ 97.8%). The main route of elimi
nation
of GS-9876 is likely  hepatobiliary  with ≤ 5.1% orally  dosed radioactivity  found in rat urine and
69.4% in bile of BDC rats.
GS-9876 undergoes slow oxidative metabolism in human hepatocy tes. Comparison of
metabolism in hepatocy tes from rats, dogs, monkey s, and humans did not identify  any
metabolites unique to humans, supporting the selection of rat and cy nomolgus monkey  as
toxicology  species. No detectable turnover of GS -9876 by [CONTACT_647802]
(CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, C YP2D6, or CYP3A4) was observed
confirming the high metabolic stability  in human hepatocy tes. The clearance of GS -[ADDRESS_867500] on the activities of human CYP1A2, CYP2B6, CYP2C8,
CYP2C9, CYP2C19, CYP2D6, or CYP3A. GS -9876 was a weak inhibitor of human UGT1A1 
(IC50 = 31.1 μM). The low sy stemic concentrations anticipated in the clinic for GS-9876 make it 
unlikely to cause drug -drug interactions in vivo through inhibition of human CYP enzy mes or 
UGT1A1.
GS-
9876 is a weak inhibitor of the efflux transporters P- gp (IC50 > 23.2 μM) and BCRP
(IC50>100 μM) as well as the hepatic uptake transporters OATP1B1 (IC50 = 10.3 μM) and
OATP1B3 (IC50 = 12.3 μM). The low dose and low systemic concentrati ons anticipated in the
clinic for GS -[ADDRESS_867501] been dosed with GS -9876 in twoclinical 
studies.
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page20 08 April2016Completed Clinical Trial
GS-US-379-1372: This was a first
-in-human, Phase 1, single -dose ranging study  of GS-[ADDRESS_867502], and drug-drug 
interaction potential using a representative acid reducing agent (omeprazole). 
Ongoing Clinical Trial
GS-US-
379-1900: This is asingle-and multiple-dose Phase [ADDRESS_867503] been
implicated as play ing a critical role in the pathogenesis of RA as demonstrated by  [CONTACT_647803] -CD20 monoclonal antibody , rituximab, in RA patients {Leandro et al 2006 , 
Navarro-Millan et al 2013 }.B cells contribute to the pathogenesis of RA through their ability  to 
act as antigen presenting cells ( APCs)presenting self-antigens to auto -reactive T cells 
{Shlomchik 2008
}, and through the production of autoantibodies and pro-inflammatory  
cytokines {Martin et al 2006 , Song et al 2010}. As a critical mediator of BCR signaling, SYK
inhibition suppresses BCR- stimulated proliferation, co -stimulatory  molecule expression, and 
autoantibody  production in B cells {Braselmann et al 2006 , Coffey et al 2012}. 
Additionally , SYKinhibition suppresses IC-stimulated cy tokine release f rom 
monocytes/macrophages and prevents osteoclastogenesis {Liao et al 2013
}. Spleen ty rosine 
kinase is expressed in the rheumatoid sy novium {Cha et al 2006 }and SYKinhibition reduces 
cellular infiltrates into s ynovial tissue {Coffey et al 2012 }. Pharmacologic inhibition of SYKhas 
been shown to inhibit disease progression and reduce inflammation in multiple animal models of 
RA, and has demonstrated disease modify ing anti-rheumatic drug (DMARD) activity  on
endpoints such as cartilage destruction and bone erosion
{Coffey et al 2012 , Liao et al 2013
, 
Pi[INVESTIGATOR_194016] 2007 }.  A consistent finding in these nonclinical studies is that significant efficacy  can 
be achieved with minimum plasma concentrations (C min) that result in target coverage less than 
50% {Liao et al 2013}.
GS-[ADDRESS_867504] that inhibition of SYK may decrease several 
pathologically active mechanisms implicated in RA including B-cell activation, T -cell 
costimulation, and cytokine release. 
This study is designed to evaluate the efficacy, safety, tolerability, PK, and [COMPANY_003] 
1.5. Rationale for Dose Selection 
In the rat CIA model, predicted GS-9876 exposure at the 30 mg and 10 mg QD doses are 
estimated to provide 75% and 37% of the maximal treatment response observed with GS-9876, 
respectively. The maximal treatment response observed with GS-9876 in this model was similar 
to the positive control dexamethasone. In the multiple ascending dose study (GS-US-379-1900) , 
doses up to 30 mg QD of GS-9876 for 7 days were well tolerated in healthy volunteers. 
Therefore both doses (10 mg QD and 30 mg QD) are expected to be safe and have the potential 
to be efficacious in RA. 
1.6. Risk/Benefit Assessment for the Study 
As of08 April 2016, GS-9876 has been well tolerated by 62 healthy subjects. In the clinical 
studies GS-US-379-1372 (single ascending dose) and GS-US-379-1900 (cohorts 1 and 2; 
multiple ascending dose over 7 days), no risks were identified, and observed AEs were mainly 
Grades 1 and 2 in severity. The majority of AEs were assessed by [CONTACT_647804]-9876. The majority of graded laboratory abnormalities was Grade 1 or Grade 2 and mostly 
related to cholesterol. No prolongation of bleeding time duration was noted during the study. No 
clinically significant changes in vital signs, physical findings, or ECGs were reported during this 
study and no clinically relevant QTcF interval prolongation was noted in time matched ECGs in 
cohort 1 and cohort 2. 
In the repeat dose toxicology studies, dose-dependent effects on lymphocytes in both rats and 
monkeys were consistent with the expected pharmacology of SYK inhibition. Effects on 
hemostasis were observed in rats and monkeys, with increased erythrocyte turnover in rats at 
2: 10 mg/kg/day, and hemorrhage and thrombosis in monkeys at 2: 20 mg/kg/day. At higher doses 
in rats (2: 30 mg/kg/day), mortality associated with bacterial infections, likely resulting from the 
immunomodulatory activity of GS-9876, was seen. Additional findings included lymphoid 
depletion in the thymus, changes in the pancreas, with secondary effects related to the 
immunomodulatory activity of GS-9876, and likely opportunistic bacterial infection, observed in 
several tissues. The NOAEL in rats was 10 mg/kg/day after 26 weeks dosing. For the proposed 
30 mg dose in planned Study GS-US-379-1582 , estimated exposure margins are 2.4-/5.9-fold 
based on exposures at the NOAELs in the 26 week study in male/female rats. Patients will be 
closely monitored for any infection, changes in the differential CBC and cell subsets. 
In monkeys, the NOAEL in the 28-day study was identified at 10 mg/kg/day, which was 
associated with AUCo-24 hr of 4290 ng•hr/mL. In the 13-week monkey study, there were no 
effects on hemostasis, and the NOAEL was the high dose of 15 mg/kg/day. However in the 
ongoing 39-week study, one 15 mg/kg/day monkey was euthanized moribund during Week 22 
CONFIDENTIAL Page 21 08 April2016 
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page22 08 April2016with persistent fecal change s, weight loss, deteriorating clinical condition, and large bowel 
inflammation. [COMPANY_009] considers it prudent to limit exposures in StudyGS-US-379-
1582to mean 
exposures achieved in monkey s at the 10 mg/kg/day  mid-dose at Week 13 of the 39- week study  
(6750ng•h/mL). For the highest proposed dose of 30 mg in this study the 
estimated exposure 
margin is 2.7- fold based on exposures at the NOAELin the 13- week monkey  study.
In clinical studies GS -US-379-1372 and GS -US-379-1900 (cohorts 1 and 2) no change in 
platelets numbers, prothrombin time (PT), partial thromboplastin time (PTT), international 
normalized ration (INR) as well as bleeding time were observed. The risk for bleeding at the 
doses proposed for this POC studyis therefore considered to be low.
An independent and experienced Data Monitoring Committee (DMC) appointed to monitor the 
study will provide an additional level of risk mitigation. Refer to Section 8.9Data Monitoring 
Committee.
The overall risk:benefit balance of this study  is considered favorable. For additional information 
about the risks of GS -9876, reference is made to the investigator brochure.
1.7. Compliance
This study  will be conducted in compliance with this protocol, GCP, and all applicable 
regulatory  requirements.
GS-9876 
Protocol GS-US-379-1582 
[COMPANY_009] Sciences, Inc. 
2. OBJECTIVES 
The primary objective of this study is: Original 
• To evaluate the effect of GS-987 6 versus placebo for the treatment of signs and symptoms of 
RAin subjects with active RA as measured by [CONTACT_647805]28 (CRP) at 
Week 12 
The secondru.y objectives of this study are: 
• To evaluate the safety and tolerability of GS-9876 in subjects with RA 
• To explore the effect of GS-9876 on other disease-specific outcomes in RA 
The explorat01y objectives of this study are: 
IT 
I 
I 
CONFIDENTIAL Page23 08 April2016 
GS-9876 
Protocol GS-US-379-1582 
[COMPANY_009] Sciences, Inc. 
3. STUDY DESIGN 
3.1. Endpoints 
The primaty endpoint of this study is: 
• Change from baseline in DAS28 (CRP) at Week 12 
The secondaty endpoints of the study are: 
• The proportion of subjects who achieve ACR 20/50/70 at Week 12 
• Change from baseline in HAQ-DI score at Week 12 
The explorat01y endpoints include: 
IT 
I 
I 
I 
I 
I 
3.2. Study Design Original 
This is a randomized , double-blind , placebo-controlled, POC study evaluating the safety, 
tolerability , and efficacy of GS-9876 in adult male and female subjects with active RA despi[INVESTIGATOR_647789] (either alone or in combination with 
bDMARDs). 
A total of approximately 60 subjects will be randomized in this study. 
CONFIDENTIAL Page24 08 April2016 
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page25 08 April2016Figure3-1. Study Schema
3.3. Study Treatments
Following completion of Screening assessments, eligible subjects will be randomized in a 
blinded fashion in a 1:1:1 ratio as follows:
Group 1:
GS-9876 (30 mg QD) (N=20)
Group 2:
GS-9876 (10 mg QD) (N=20)
Group 3:
GS-9876 PTM (QD) (N=20)
Randomization will be stratified b y prior inadequate response to biologic therap y and geographic 
region.  
3.4. Duration of Treatment
Subjects will be treated for up to [ADDRESS_867505] 
discontinuation. Study  medication may be discontinued in the following instances:
Intercurrent illness that would, in the judgment of the investigator affect assessment of 
clinical status to a significant degree . Following resolution of intercurrent illness, the subject 
may resume study  dosing at the discretion of the investigator.

GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page26 08 April2016Unacceptable toxicity , as defined in the toxicity  management section of the protocol, or 
toxicity that, in the judgment of the investigator , compromises the ability  to continue 
study-specific procedures or is considered not to be in the subject’s best interest
Subject request to discontinue for an y reason
Subject noncompliance
Subjects use of non- permitted concurrent therap y
Serious infections (those requiring parenteral antimicrobial therap y or hospi[INVESTIGATOR_059]
)
Any opportunistic infections
Complicated herpes zoster infection (multi- dermatomal, disseminated, ophthalmic or CNS 
involvement)
Pregnancy  during the study ; refer to Appendix 5
Investigator discretion
Discontinuation of the study  at the request of [COMPANY_009] , regulatory  agency or an Institutional 
Review Board (I RB)/Independent Ethics Committee (IEC)
Laboratory  abnormalities:
■ 2 sequential total WBCs <2000 cells/mm3(SI: <2.0x109cells/L).
■
2sequential neutrophil counts <1000 neutrophils/mm3(SI: <1.0x109cells/L).
■ 2sequential ly mphocyte counts <750 ly mphocytes/mm3(SI: <0.75x109cells/L).
■ 2sequential hemoglobin values <8.0 g/dL (SI: <80 g/L).
■ 2 sequential platelet counts <75,000 platelets/mm3(SI: <75.0x109cells/L).
■ 2sequential AST or ALT elevations >3xUL N with ≥1 total bilirubin value >2xUL N.1
■ [ADDRESS_867506] or ALT elevations >3xUL N accompanied by  [CONTACT_386041] (INR).1
                                                
1In each case, there is a need for additional investigations, such as review of ethanol, recre ational drug and dietary 
supplement consumption; testing for acute hepatitis A, B or C infection and biliary tract imaging should be promptly 
discussed with the study Medical Monitor .
GS-9876 
Protocol GS-US-379-1582 
[COMPANY_009] Sciences, Inc. Original 
3.6. • 2 sequential ASTor ALT elevations >5xULN, regardless of total bilimbin or 
accompany ing symptoms.1 
• 2 sequential increases in semm creatinine >50% over the average of Screening and 
Day 1 values. 2 
• After becoming aware of any of the above described abnonnallaborat01y changes 
occmTing at any one time, an unscheduled visit (i.e. second sequential) must occur to 
retest within [ADDRESS_867507]'s interest so that data can 
End of Study 
End of Study is defined as when the last patient has completed up to [ADDRESS_867508] 
patiicipated on this study and the long tenn care of subjects will remain the responsibility of their 
primaty treating physician. 
3.8. Pharmacoki netic (PK) Assessments 
Plasma concentrations ofGS-9876 will be measured and PK parameters detetmined. Plasma 
concentrations of GS-9876 metabolites may be detetmined and PK parameters may be explored, 
as applicable. PK sampling will occur relative to study dmg dosing at Weeks 2, 8, and 12 or ET, 
corresponding to a trough concentration taken approximately 24 hours after the previous dose of 
GS-9876, but prior to the next dose of GS-9876. At Week 4, PK sampling will occur at 2 hours 
postdose. The samples will be used to evaluate PK of GS-9876 and may also be used to measure 
protein binding of GS-9876. Plasma concentrat ions of GS-9876 metabolites and/or MTX may be 
detetmined. 
[COMPANY_003] 
[ADDRESS_867509] should exhibit elevations in serum creatinine :;::33 % 
above the average of Screening and Day 1 values, they should be re-tested every 1 to 2 weeks until the senun 
creatinine elevation is fully reversed to within 10% of the average of Screening and Day 1 values. 
CONFIDENTIAL Page27 08 April2016 
GS-9876 
Protocol GS-US-379-1582 
[COMPANY_009] Sciences, Inc. 
3.9. Biomarker Testing 
PO Original 
Sampling for markers relevant to inflammation (including but not limited to disease-associated 
markers ofRA and/or the SYK pathway) may be perfonned at Baseline, Day 1, Week 4, and 
Week 12 or ET. Sampling time points may be modified by [CONTACT_647806]. Samples for CRP will be drawn at evety visit. 
The testing outlined in this protocol is based upon the cunent state of scientific knowledge. It 
may be modified dming or after the end of the study to remove tests no longer indicated and/or 
to add new tests based upon the growing state of knowledge. Samples may be stored at [COMPANY_009] 
Sciences for a period of up to [ADDRESS_867510] an inadequate 
response to MTX (either alone or in combination with bDMARDs). In order to manage the total 
study enrollment, [COMPANY_009] , at its sole discretion, may  suspend screening and/or enrollment at any  
site or study -wide at any  time.
4.2. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study.
1)Male or female subjects who are between 18and75yearsof age, inclusive ,on the day  of 
signing informed consent
2)Have a diagnosis of RA as defined b y the [ADDRESS_867511] Rheumatism Collaborative I nitiative 
Classification Criteria for Rheumatoid Arthritis
(Appendix6)
3)Active RA disease as defined by  a TJC of ≥6 (out of 68), a SJC of  ≥6 (out of 66), and 
a 
CRP ≥ 5 mg/l
4)Inadequate response to treatment with oral or parenteral MTX 7.5 to 25 mg/week 
continuously  for at least [ADDRESS_867512] 
dose of study  drug
5)Subjects must be receiving a folic or folinic acid supplementation at a stable dose . Subjects 
who are not t aking folic or folinic acid at Screening should be initiated on an adequate dose 
of folic acid ( >
5 mg/week total dose or as per local practice) or equivalent and maintained 
throughout the stud y.
6)Use of oral corticosteroids of no more than [ADDRESS_867513] dose of study  drug  
7)NSAIDs or other analgesics (including aspi[INVESTIGATOR_248] ≤ 100 mg dail y) are allowed if doses are 
stable for at least [ADDRESS_867514] dose of study  drug  
8)Able and willing to sign the informed consent as approved b y the IRB/IEC. Written consent 
must be provided before initiating an y Screening evaluations. Subjects must have read and 
understood the informed consent form (I CF), must fully  understand the requirements of the 
study, and must be willing to compl y with all study visits and ass essments.
9) A negative serum pregnancy  test is required for female subjects 
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page30 08 April201610)Lactating females must agree to discontinue nursing before the investigational medicinal 
product (IMP)is administered.
11) Male subjects and female subjects of childbearing potential w ho engage in heterosexual 
intercourse must agree to use protocol specified method(s) of contraception as described in 
Appendix 5.
4.3.
Exclusion Criteria
1)Prior treatment with B -cell depleting agents (eg, rituximab), unless more than 6 months prior 
and documente d return of CD19+ cells
2)Prior treatment with an y commerciall y available or investigational SYK inhibitor 
3)Current treatment with any  other cDMARD other than MTX and/or HCQ(unless appropriate 
wash out as defined in Section 5.5
)
4)Current treatment with any  bDMARD (unless appropriate wash out as defined in 
Section5.5). Prior failure to treatment with bDMARDs is not an exclusion criterion.
5) QT interval corrected for heart rate using the Fredericia formula (QTcF) > 450 msec 
determined b y the average of values at the S creening visit
6)History of any major bleeding event defined as Grade 3 severit y and above [as defined b y 
modified the Common Terminology  Criteria for Adverse Events (CTCAE) 4.03] within the 
last year or personal or family  history of bleeding disorder
7)If no history  of a documented negative TB test within the last [ADDRESS_867515] be performed 
according to local standards. Subjects 
with a positive Quantiferon at S creening are not 
eligible
8)Ongoing treatment with moderate or strong CYP3A inducers or inhibitors or within 2 weeks 
prior to study  drug administration
9)Joint injections within [ADDRESS_867516] dose of study  drug
10)Administration of a live or attenuated vacc ine within 30.
11)Participation in any  investigational drug/device clinical study within 4 weeks or 5 half -lives 
prior to Screening, whichever is longer. Exposure to investigational biologics should be 
discussed with the sponsor. 
12)Have a diagnosis of an y generalized musculoskeletal disorder (eg, generalized osteoarthritis, 
or systemic inflammatory  condition other than RA such as, but not limited to: juvenile 
idiopathic arthritis, Felt y’s syndrome, ankylosing spondy litis, reactive arthritis, psoriatic 
arthritis, inflammatory  bowel disease associated arthropaties, s ystemic lupus ery thematosus, 
scleroderma inflammatory m yopathy, mixed connective tissue disease, an y overlap 
syndrome, s ystemic vasculitis or gout [participants with secondary  Sjogren's s yndrome or 
secondary limited cutaneous vasculitis with RA are not excluded ]).
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page31 08 April201613)History of or current moderate to severe congestive heart failure ([LOCATION_001] Heart 
Association [NYHA] class III or IV), or within the last [ADDRESS_867517] at risk by  
[CONTACT_9286] .
14)History of malignancy  within the past 5 years prior to Screening (except for adequatel y 
treated or excised basal cell carcinoma or non -metastatic squamous cell carcinoma of the 
skin or cervical carcinoma in situ with no evidence of recurrence). 
15)History of lymphoproliferative disease or possible current l ymphoproliferat ive disease
16)History of demyelinating disease or current signs and symptoms suggestive of dem yelinating 
disease, or immediate family  history of demyelinating disease.
17)History of organ 
or bone marrow transplant.
18)Positive serology  for human immunodeficiency  virus (HIV) 1 or 2, hepatitis B virus 
(i.e.,surface antigen [Ag] or core antibod y [Ab] positive) or hepatitis C virus (i.e., HCV Ab 
positive) or an y history of infectious hepatitis from any cause with the exception of hepatitis 
A.
19)History of opportunistic infection or immunodeficiency  syndrome.
20)Known active infection of an y kind (excluding fungal infections of nail beds) or an y major 
epi[INVESTIGATOR_647790] -infectives within 
4weeks of Screening or 8 weeks of Day 1 visit or completion of oral anti -infectives within 
2weeks of the Screening or 6 weeks of Day  1 visit.
21)Currently  on any therapy for chronic infection (such as pneumocy stis, cytomegalovirus, 
herpes zoster, and aty pi[INVESTIGATOR_4017]). Past history  of disseminated Staphy lococcus 
aureus or disseminated Herpes simplex infection.
22)History of symptomatic herpes zoster or herpes simplex infection within [ADDRESS_867518] history  of disseminated/complicated herpes zoster infection 
(multi-dermatomal involvement, ophthalmic zoster, central nervous s ystem involvement or 
postherpetic neuralgia).
23)History of an infected joint prosthesis or other implanted device with retention of the 
prosthesis or device in situ.
24)History within the previous 2 years or current evidence of drug or alcohol abuse.
25)Any condition including active fibrom yalgia that based on the investigator’s opi[INVESTIGATOR_454155] .
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page32 08 April201626)Any condition or circumstances wh ich in the opi[INVESTIGATOR_647791] a subject unlikel y or unable to complete the study or compl y with study  procedures and 
requirements.
27)Significant blood loss (>450 mL) or transfusion of any  blood product within 12 weeks prior 
to Day 1.
28)Male subjects must refrain from sperm donation throughout the study  periodand continuing 
for at least [ADDRESS_867519] dose of study  drug.
29)Female subjects must refrain from egg donation or harvest throughout the study  period and 
continuing for at least [ADDRESS_867520] dose .
30)Subjects have not donated blood within [ADDRESS_867521] dose of study  drug.
31)The results of the following laboratory  tests performed at the central laboratory  at Screening 
meet any of the criteria below:
a)Hemoglobin <8.0 g/dL (International Sy stem of Units [SI ]: <
80g/L);
b)White blood cells <3.0 x 103cells/mm3(SI: <3.0x 109cells/L); 
c)Neutrophils <1.5 x
103cells/mm3(SI: <1.5x 109cells/L);
d)Lymphocytes <0.5x 103cells/mm3(SI: <0.5x 109cells/L);
e)Platelets <100 x 103cells/mm3(SI: <100x 109cells/L);
f)Alanine aminotransferase (A LT) or aspartate aminotransferase (AST) ≥1.5xULN;
g)Total bilirubin level ≥ 2x ULN unless the subject has been diagnosed with Gilbert’s  
disease and this is clearly documented;
h)Creatinine clearance <60
mL/min based on the Cockcroft -Gault (CG) formula3
                                                
3Creatinine clearance (mL/min) = [ (140 –age) * weight in kg] / [ 815 * serum creatinine in mmol/L ]
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page33 08 April20165. INVESTIGA TIONAL  MEDICINAL P RODUCTS
5.1. Randomization, Blinding and Treatment Codes
An Interactive Weband Mobile Response Sy stem (IXRS) will be employ ed to manage subject 
randomization and treatment assignments . It is the responsibility  of the 
investigator to ensure that 
the subject is eligible for the study  prior to enrollment. Subjects will be assigned a Screening 
number at the time of consent.
5.1.1. Procedures for Breaking Treatment Codes
In the event of a medical emergency  where breaking the blind is required to provide medical care 
to the subject, the investigator or qualified designeemay obtain treatment assignment directly  
from the IXRS sy stem for that subject. [COMPANY_009] recommends but does not require that the 
investigator contact [CONTACT_10848]. Treatment assignment 
should remain blinded unless that knowledge is necessary  to determine subject emergency  
medical care. The rationale for unblinding must be clearly explained in source documentation 
and on the electronic case rep ort form (eCRF), along with the date on which the treatment 
assignment was obtained. The investigator is requested to contact [CONTACT_647807] y treatment unblinding.
Blinding of stud y treatment is critical to the integrity of this clinical trial and therefore, if a 
subject’s treatment assignment is disclosed to the investigator, the subject will have study  
treatment discontinued. All subjects will be followed until study  completion unless consent to do 
so is specificall y withdrawn by  [CONTACT_423].
[COMPANY_009]Drug Safet y and Public Health (DSPH) may independentl y unblind cases for expedited 
reporting of suspected unexpected serious adverse reactions (S[LOCATION_003]Rs).
5.2. Description and Handling of GS -9876and Placebo
-To-Match (PTM) GS -
9876
5.2.1. Formulation
GS-9876 will be supplied as 10 or 30 mg tablets that are round, biconvex, plain- facedandfilm-
coated blue . Each tablet contains either 1 0mg or 30 mg ofGS-9876 free base as the succinate 
form (GS-9876-02). TheGS-9876 tablets contain commonly used excipi[INVESTIGATOR_614745], mannitol, croscarmellose so dium, magnesium stearate, pol yvinyl 
alcohol, pol yethyleneglycol, titanium dioxide, talc, and FD&C blue # 2
/indigo carmine 
aluminum lak e. 
Matching placebo tablets will be sup plied that are identical in phy sical appeara nce to the 
10 or
30mg GS-9876tablets and contain the following inactiv e ingredients: 
microcrystallinecellulose, lactose, croscarmellose sodium , magnesium stearate, 
polyvinylalcohol, pol yethylene glycol, titanium dioxide, talc, and FD&C blue #2/indigo carmine 
aluminum lak e.
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page34 08 April20165.2.2. Packaging and Labeling
GS-9876 tablets, 10 mg or 30 mg, and PTMtablets are packaged in white, hig h-density
polyethy
lene(HDPE)bottles.Each bottle contains 30 tablets, silica gel desi ccant and polyester 
packing material. Each bottle is enclosedwith a white, continuous thread, child -resistant 
polypropylene screw cap with an induction -sealedandaluminum -faced liner.
Study drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the [LOCATION_002] Food and Drug Administration 
(FDA), European Union ( EU)Guideline to Good Manufacturing Practice -Annex 13 
(Investigational Medicinal Products), and/or other local regu lations.
5.2.3. Storage and Handling
GS-9876 tablets and PTMtablets should be stored at controlled room temperature of 25ºC 
(77ºF); excursions are permitted between15ºC and 30ºC (59ºF and 8
6ºF).Storage conditions are 
specified on the label. Until dispensed to the subjects, all bottles of study drugs should be stored 
in a securely  locked area, accessible only  to authorized site personnel.
To ensure the stability and proper identification, study drugs should not be stored in a container 
other than the container i n which they  were supplied. 
Consideration should be given to handling, preparation, and disposal through measures that 
minimize drug contact [CONTACT_10850] . Appropriate precautions should be followed to avoid direct 
eye contact [CONTACT_90265]. 
5.3. Dosage and Administration of GS -9876
GS-
9876 30mg (1 x 30 mg tablet), GS -9876 10 mg (1 x 10 mg tablet), or GS-9876 PTM
(1tablet)will be provided by  [CONTACT_10869], Inc .andare to be administered orallyonce daily
with water . The study drug should be swallowed whole.GS-[ADDRESS_867522] in -clinic study  procedure (after all other procedures for that visit have 
been completed). At Weeks2, [ADDRESS_867523] been completed (eg, PK sample collection ).At Week 4, subjects will 
be instructed to take their dose in clinic as the first study  procedure prior to any  others scheduled 
for that visit. 
For missed dose(s) of study  medication, subject should be instructed to take the missed dose(s) 
of study medication, as soon as possible, during the same day . If more than [ADDRESS_867524] visit or during the visit (as applicable). Concomitant medications include
prescription, non -prescription medications, therapi[INVESTIGATOR_014], dietary  supplements, and minerals.
Allowed Medications:
Subjects must have taken oral or parent eral MTX 7.5 to 25 mg/we ek continuously  for at least 
12weeks, with at least [ADDRESS_867525] study  doseand throughout the 
duration of the study . Subjects will continue to receive stable weekl y doses of M TX. Further 
information regarding side effects, dosage and administration is available in the current local 
prescribing information.
Subjects are allowed to remain on hy droxychloroquine, with at least [ADDRESS_867526] study  dose
Chronic use of s ystemic corticosteroids up to a maximum of 10 mg/day  of prednisone or 
equivalent is allowed if dose is stable for at least [ADDRESS_867527] study dose and 
maintained at a stable dose throughout the stud y.
NSAIDs or other analgesics (includi ng aspi[INVESTIGATOR_248] ≤ 100 mg) are allowed if doses are stable for 
at least [ADDRESS_867528] study  dose. 
For painwhile on study , the patient may  take acetaminophen or other non- NSAID pain 
medications as directed by  [CONTACT_647808].  Any scheduled or pro re nata ( prn)pain 
medication should be taken after the Baseline and Week 12 visits are completed .
Prohibited Medications:
Any herbal/natural supplements, unless approved by  [CONTACT_1689]
Any and all illegal or illicit drug use, including use of prescription drugs outside the ca re of 
the prescribing ph ysician
Changes in the doses of background MTX, anti -malarial therap y, corticosteroids and/or 
NSAIDS are not permitted during the stud y period except to avoid adverse effects
Use ofmoderate orstron
g CYP3A4 inhibitors or moderate or strong CYP3A4 inducers 
within [ADDRESS_867529] dose of stud y drugand while on study  drug is prohibited
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page36 08 April2016The following medications are prohibited from [ADDRESS_867530] dose of study drug 
and throughout the study: 
minocycline, penicillamine, sulfasalazine, anakinra, etanercept , etanercept biosimilar , 
azathioprine, cy closporine, tacrolimus, sirolimus, everolimus, my cophenolate mofetil , 
tofacitinib
The following medications are prohibited within [ADDRESS_867531] dose of study  drug and 
throughout the stud y: 
infliximab, infliximab biosimilar, golimumab, certolizumab pegol, abatacept, 
tocilizumab , adalimumab
Treatment with antibiotics for a clinical infection or other medical condition within [ADDRESS_867532] dose 
Previoustreatment with B-cell depleting agents (ie, rituximab) within 6 monthsof treatment 
Treatment with an y other investigational stud y drug within 1 month prior or within 
5half-
lives of the prior investigational agent (whichever is longer) prior to S creening
Prior treatment with an y commerciall y available or investigational SYKinhibitor 
Joint injections during the course of the study are not permitted .If a joint injection has been 
used within [ADDRESS_867533] dose, the joint will be considered unevaluable throughout the 
study.
Concurrent therap y with any anti -coagulant ( eg, coumadin [warfarin], any Vitamin K 
antagonist, any novel oral anticoagulant, an y heparin or low molecular heparins, inhibitors of 
factor Xa) 
Concurrent therap y with any anti -platelet therap y (eg,adenosine diphosphate [ ADP]receptor 
inhibitors, phosphodiesterase inhibitors, PAR- 1 antagonists, Gl ycoprotein 2b/3a inhibitors) 
with the exception of ≤ 100 mg daily of aspi[INVESTIGATOR_647792]:
Vaccination with live components is prohibited during the stud y and for [ADDRESS_867534] that exposure should be avoided following vaccination 
with these vaccines for the stated time period:
varicella or attenuated t yphoid fever vaccination for 4 weeks following vaccination
oral polio vaccination for 6 weeks following vaccination
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page37 08 April2016attenuated rotavirus vaccine for 10 day s following vaccination
inhaled flu vaccine for [ADDRESS_867535] on immune re sponses 
following vaccination.
Examples of representative medications which are prohibited are listed below: 
Table5-1. Examples of Disallowed Medications
Drug Class Agents Disallowed
Strong CYP3A4 Inhibitorsaclarithromycin, conivaptan,  itraconazole, ketoconazole, nefazodone, 
posaconazole, telithromycin, voriconazole , ritonavir, cobicistat, telaprevir, 
boceprevir, grapefruit juice, idelalisib, 
Strong CYP3A4 Inducersbcarbamazepi[INVESTIGATOR_050], phenytoin, rifampin, fosphenytoin, pentobarbital, primidone, 
rifabutin, rifapentine, phenobarbital , mitotane, avasimibe, St. John’s Wort
Moderate CYP3A4 Inhibitorsafluconazole, erythromycin, diltiazem, dronedarone, aprepi[INVESTIGATOR_053], imatinib, 
verapamil, tofisopam, ciprof loxacin, cimetidine , cyclosporine , Schisandra 
sphenanthera
Moderate CYP3A4 Inducersbefavirenz, tipranavir/ritonavir, bosentan, thioridazine, nafcillin, talviraline, 
lopi[INVESTIGATOR_054], modafinil, etravirine, lersivirine, semagacestat , genistein
Immunosuppressant s mycophenolate mofetil, azathioprine, quinacrin, gold, leflunomide
Calcineurin inhibitor cyclosporine, tacrolimus
mTOR inhibitor sirolimus, everolimus
Herbal/Natural Supplementsdgrapefruit juicea, St. John’s Wortb, fish oil, borage oil, Schisandra 
sphenanthera
Anti-platelet adenosine diphosphate(ADP) receptor inhibitors, phosphodiesterase 
inhibitors, PAR -1 antagonists, Glycoprotein 2b/3a inhibitorsc
Anti-coagulant warfarin, any Vitamin K antagonist, any novel oral anticoagulant, any heparin 
or low molecular heparins, 
inhibitors of factor Xa
aIn vitro data indicate GS-[ADDRESS_867536] is on study drug and 2 weeks prior to study drug administration.
c≤ 100 mg aspi[INVESTIGATOR_279370] 
d Herbal/Natural supplements not listed require Medical Monitor review and approval.
GS-[ADDRESS_867537] Accountability andDisposal or Return
The investigator is responsible for ensuring adequate accountability  of all used and unused IMP.
This includes acknowledgement of receipt of each shipment of IMP(quantity and condition). All 
used and unused IMPdispensed to subjects must be returned to the site.
GS-9876 accountability  records will be provided to each stud y site to:
Record the date received and quantity  of IMP; 
Record the date, subject number, subject initials, 
and the IMP number dispensed ;and
Record the date, quantity of used and unused IMPreturned, along with the initials of the 
person recording the information.
For additional information about study  drug accountability  and return, refer to Section 9.1.7.
GS-[ADDRESS_867538] research organization 
(CRO).
The study  center will not initiate dosing until:
The IRB and IEC andother applicable regulatory agencies have reviewed and approved the 
study and the informed consent document;
All requested regulatory  documents have been submitted to and approved by [CONTACT_10866];
A Master Services Agreement and/or Study Agreement is executed;
The study  initiation meeting has been conducted by  [CONTACT_90269] (or designee).
The initiation meeting will include but is not limited to a review of the protocol, the IB, stud y 
drugs,and investigator responsibilities.
Documentation of the personally  signed and dated informed consent of each subject, using the 
study-specific, IRB -approved Informed Consent Forms (ICF), is required before initiating the 
screening process. 
6.1. Subject Enroll ment and Treatment Assignment
It is the responsibility  of the investigator to ensure that subjects are eligible to participate in the 
study prior to enrollment and continue to remain eligible throughout the study .
Once informed consent has been obtained, a ll screening tests and procedures have been assessed, 
and study  eligibility  has been confirmed, eligible subjects will be randomized to study  treatment
as described in Section 5.1
.
6.2. Pretreatment Assessments
6.2.1. Screening Visit( within 28 days prior to randomiza tion)
Written informed consent must be obtained from each subject before initiation of any  visit 
procedures. After a subject has provided informed consent, the investigator will determine if the 
subject is eligible for participation in the study .  Subjects will be screened within 28 day s before 
randomization to determine eligibility  for participation in the study .The assessment will 
include 
a review of the Inclusion/Exclusion criteria and completion of all Screening Visit procedures as 
outlined in Appendix 2. A sufficient number of subjects will be screened to identify
approximately 60
subjects for enrollment.
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page40 08 April2016The following will be performed and documented at S creening:
Obtain written informed consent
Obtain medical history including but not limited to RA,prior RA medication history any 
personal or family  histories of bleeding disorders
Perform c omplete ph ysical examination (refer to Appendix 9)
Obtain 
vital signs, to include height and weight at Screening
(refer to Appendix 9)
Complete 12 -lead ECG (refer to Appendix 9)
Perform 66 swollen and 68 tender joint count assessment (refer to Appendix 7and 
Appendix 9
)
Obtain blood samples for (refer to Appendix 3)
:
Hematology , Chemistry , and Coagulation
CRP
Leukocyte subsets
Serology (HIV, HCV, and HBV)
Serum pregnancy  test
RNA
Perform Quantiferon test, as applicable (refer to 
exclusion criteria)
Obtain a CD19 count, as applicable (refer to exclusion criteria)
Obtain urine for u rinalysisand urine drug screen ( refer toAppendix 3)
Collect biomarker samples
Record any serious adverse events (SAEs) and all AEsrelated to protocol mandated 
procedures occurring after signing of the consent form ( refer toSection7)
.
Record an y prior and concomitant medications
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic after screening for randomization into the study .
From the time of obtaining informed consent through the first administration of investigational 
medicinal product, record all SAEs, as well as any AEsrelated to protocol -mandated procedures 
GS-[ADDRESS_867539] medical occurrences observed during the 
screening period, including exacerbation or changes in medical history are to be captured on the 
medical history  eCRF. See Section 7Adverse Events and Toxicity  Management for additional 
details.
Screening labs may  be repeated once within 28 day s prior to administration of study  drug to rule 
out laboratory  error.
6.3. Randomization (Day 1)
Subjects who meet all inclusion and exclusion criteria and complete screening will return for 
randomization into one of the three treatments as described in Section 3.3. Randomization will 
be completed as described in Section 5.1
.
6.4. Treatment Assessments
6.4.1. Day 1
Study procedures and assessments are outlin ed in Appendix 2.The HAQ-DI, Patient’s 
Assessment of Pain, and Patient’s Global Assessment of Disease Activity  are recommended to 
be done prior to the 66 swollen and 68 tender joint count assessments and before an y invasive 
studyprocedures. Blood draws should be done at t he end of the study visitprior to dosing .
The following will be performed and documented on Day  1, within a +
3-day window:
Confirm study  eligibility
Perform s ymptom driven phy sical examination 
Obtain vital signs 
Perform 12- lead ECG (predose)
AssessAEs and concomitant medications
Subject completes disease specific questionnaires and activity  scales(refer to Appendix 9): 
HAQ-DI
Patient’sAssessment of Pain
Patient’sGlobal Assessment of Disease Activity   
Perform 
66 swollen and 68 tender joint count assessment (refer to Appendix 9)
Investigator completes Physician’sGlobal Assessment of Disease Activity (refer to 
Appendix 9)
GS-9876 
Protocol GS-US-379-1582 
[COMPANY_009] Sciences, Inc. 
• Obtain blood samples for: 
-Hematology, Chemistiy, and Coagulation 
-CRP 
-Leukocyte subsets 
-RF/CCP 
-IgA, IgG, and IgM 
-RNA Original 
• Obtain urine sample for urine pregnancy test for females of childbearing potential only 
• Collect biomarker samples 
• [COMPANY_003] 
• Dmg Administration 
-Dispense study chugs as directed by [CONTACT_4150] 
-Instluct the subject on the packaging , storage and administration of all study ch·ugs 
-Observe the subject taking the first dose of study ch11g and record the time of the 
first dose. Study chug should be administered as the last study procedure on Day 1. 
-Inst111ct subjects not to take study <hug until after predose assessments at Week 2, Week 
8, and Week [ADDRESS_867540] subjects not to take study ch11g until in clinic and 
instmcted to do so at Week 4. 
6.4.2. Week 2 (±3 days) 
Study procedures and assessments are outlined in Appendix 2. The following will be perfonned 
and documented at Week 2, within a± 3-day window: 
• Perfmm symptom ch·iven physical examination 
• Obtain vital signs 
• Perfmm 12-lead ECG 
• Assess AEs and concomitant medications 
• Subject completes disease specific questionnaires and activity scales: 
CONFIDENTIAL Page42 08 April2016 
GS-9876 
Protocol GS-US-379-1582 
[COMPANY_009] Sciences, Inc. 
-HAQ-DI 
-Patient's Assessment of Pain 
-Patient's Global Assessment of Disease Activity 
• Perform 66 swollen and 68 tender joint count assessment 
• Investigator completes Physician's Global Assessment of Disease Activity 
• Obtain blood samples for: 
-Hematology, Chemistry, and Coagulation 
-CRP Original 
• Obtain urine sample for urine pregnancy test for females of childbearing potential only 
• Collect PK sample (predose) 
• Study drug administration after predose assessments completed (eg, PK sample collection). 
• Complete medication pi[INVESTIGATOR_692] 
• Review study drug compliance and drug administration instructions with subject. 
6.4.3. Week 4 (± 3 days) 
Study procedures and assessments are outlined in Appendix 2. The following will be performed 
and documented at Week 4, within a± 3-day window: 
• Study drug administration Qrior to other study procedures ~[COMPANY_003] 
) ------------------~ 
~--------------------------~ 
• Perform symptom driven physical examination 
• Obtain vital signs 
• Perform 12-lead ECG 
• Assess AEs and concomitant medications 
• Subject completes disease specific questionnaires and activity scales: 
-HAQ-DI 
-Patient's Assessment of Pain 
-Patient's Global Assessment of Disease Activity 
CONFIDENTIAL Page 43 08 April2016 
GS-9876 
Protocol GS-US-379-1582 
[COMPANY_009] Sciences, Inc. 
• Perf01m 66 swollen and 68 tender joint cmmt assessme nt 
• Investigator completes Physician's Global Assessment of Disease Activity 
• Obtain blood samples for: 
-Hematology, Chemistly, and Coagulation 
-CRP 
-RNA Original 
• Obtain urine sample for mine pregnancy test for females of childbearing potential only 
• Collect biomarker samples 
• Collect PK sample (2 hours postdose) 
• [COMPANY_003] 
• Study dmg will be dispensed as directed by [CONTACT_18375]. 
• Complete medication pi[INVESTIGATOR_647793] 
• Review study d.mg compliance and dmg adminisn·ation instluctions with subject. 
6.4.4. Week 8 (± 3 days) 
Study procedures and assessments are outlined in Appendix 2. The following will be perf01med 
and documented at Week 8, within a± 3-day window: 
• Perf01m symptom driven physical examination 
• Obtain vital signs 
• Perf01m 12-lead ECG 
• Assess AEs and concomitant medications 
• Subject completes disease specific questionnaires and activity scales: 
-HAQ-DI 
-Patient's Assessment of Pain 
-Patient's Global Assessment of Disease Activity 
• Perf01m 66 swollen and 68 tender joint count assessment 
CONFIDENTIAL Page44 08 April2016 
GS-9876 
Protocol GS-US-379-1582 
[COMPANY_009] Sciences, Inc. 
• Investigator completes Physician's Global Assessment of Disease Activity 
• Obtain blood samples for: 
-Hematology, Chemist1y, and Coagulat ion 
-CRP Original 
• Obtain urine sample for urine pregnancy test for females of childbearing potential only 
• Collect PK sample (predose) 
• [COMPANY_003] 
• Study drug administration after predose assessments completed (eg, PK sample collection). 
• Study dmg will be dispensed as directed by [CONTACT_18375]. 
• Complete medication pi[INVESTIGATOR_647793] 
• Review study dmg compliance and dmg administration instmctions with subject. 
6.4.5. Week 12 (±3 days) 
Study procedures and assessments are outlined in Appendix 2. The HAQ-DI, Patient's 
Assessment of Pain, and Patient's Global Assessment of Disease Activity are recommended to 
be done prior to the 66 swollen and 68 tender joint count assessments and before any invasive 
study procedures. Blood draws should be done at the end of the study visit. 
The following will be perf01med and documented on Day I, within a± 3-day window: 
• Perf01m symptom driven physical examination 
• Obtain vital signs 
• Perf01m 12-lead ECG 
• Assess AEs and concomitant medications 
• Subject completes disease specific questionnaires and activity scales: 
-HAQ-DI 
-Patient's Assessment of Pain 
-Patient's Global Assessment of Disease Activity 
CONFIDENTIAL Page45 08 April2016 
GS-9876 
Protocol GS-US-379-1582 
[COMPANY_009] Sciences, Inc. 
• Perf01m 66 swollen and 68 tender joint cmmt assessme nt (prior to Physician's Global 
Assessme nt of Disease Activity) 
• Investigator completes Physician's Global Assessment of Disease Activity 
• Obtain blood samples for: 
-Hematology, Chemistty, and Coagulation 
-CRP 
-Leukocyte subsets 
-RF/CCP 
-IgA, IgG, and IgM 
-RNA Original 
• Obtain urine sample for mine pregnancy test for females of childbearing potential only 
• Collect biomarker samples 
• Collect PK sample (predose) 
• PD 
• Study drug administt·ation after predose assessments completed (eg, PK sample collection). 
• All study drug must be retumed by [CONTACT_1130]. Study dmg not previously retumed by [CONTACT_647809]. 
• Complete medication pi[INVESTIGATOR_692] 
• Review study dmg compliance and dmg administration insttuctions with subject. 
6.5. Early Termination(± 3 days) 
If a subject discontinues study dosing (for example, as a result of an AE), eve1y attempt should 
be made to perf01m the required study-related follow-up and procedures (see Section 3.5, 
Discontinuation Criteria). 
Evaluations indicating abn01mal results believed to be possibly or probably related to study 
treatment at the ET visit should be repeated weekly or as often as deemed appropriate by [CONTACT_192682] r tmtil the abn01mality resolves, retums to baseline visit levels, or is othe1 wise 
explained. 
CONFIDENTIAL Page46 [ADDRESS_867541] discontinues prematurely from the study, the ET evaluations and/or procedures 
should be completed as outlined in Appendix 2within [ADDRESS_867542]’s 
early terminati on 
from the study .The following will be performed and documented at ET, within a +3-day 
window:
Perform s ymptom driven phy sical examination 
Obtain vital signs 
Perform 12- lead ECG
AssessAEs and concomitant medications
Subject completes disease specific questionnaires and activity  scales: 
HAQ-DI
Patient’s Assessment of Pain 
Patient’sGlobal Assessment of Disease Activity     
Perform 66 swollen and 68 tender joint count assessment 
Investigator complete sPhysician’s Global Assessment of Disease Activity   
Obtain blood samples for:
Hematology , Chemistry , and Coagulation
CRP
RF/CCP
IgA, IgG, and IgM
RNA
Obtain urine sample for urinepregnancy  test for females of childbearing potential only
Collect biomarker samples 
Collect PK sample
6.6. Post-Treatment 
Assessments (+5 days)
Study procedures and assessments are outlined in Appendix 2. The [ADDRESS_867543]- Treatment 
Follow-Up Visit will occur 28 day s (+5 days) from the last administration of study  drug. The 
following will be performed and documented:
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page48 08 April2016Performsymptom driven phy sical examination 
Obtain vital signs 
Perform 12- lead ECG
Assess AEs and concomitant medications
Obtain blood samples for:
Hematology , Chemistry , and Coagulation
CRP
Obtain urine sample for urinepregnancy  test for females of childbearing potential only
6.7. Sample Storage
From subjects who provide additional consent, residual samples from blood drawn at all visits 
will be frozen and stored. These stored samples may  be used by  [CONTACT_647810], study  drug, or clinical laboratory  
testing to provide additional safety data. No human genetic testing will be performed without 
express consent of the study  subjects. At the conclusion of this study , these samples 
and samples 
collected for RNA may be retained in storage for [COMPANY_009] for a period of up to [ADDRESS_867544] a causal relationship with th etreatment. An AE can 
therefore be an y unfavorable and/or unintended sign, s ymptom, or disease temporally  associated 
with the use of a medicinal product, whether or not considered re lated to the medicinal product.
AEs may also include pre -or post-treatment
complications that occur as a result of protocol 
specifiedprocedures, lack of efficacy , overdose ,drug abuse/misuse reports , or occupational 
exposure.Preexisting events that increase in severity  or change in nature during or as a 
consequence of participation in the clinical study  will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such assurgery, endoscopy , tooth extraction, andtransfusion.
The condition that led to the procedure may be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected before the 
Screening visit that do not worsen
Situations where an untoward medical occurrence has not occurred (eg , hospi[INVESTIGATOR_10800] , social and/or convenience admissions)
Overdose without c linical sequelae (see Section [IP_ADDRESS])
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. It is considered to be pre -existing and should be documented on the medical history  
eCRF.
7.1.2. Serious Adverse Events
AnSAEis defined as an event that, at an y dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospi[INVESTIGATOR_10801]-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page50 08 April2016Persistent or significant disability /incapacity
A congenital anomal y/birth defect
A medicall y important event or reaction: such events may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_647794] o utcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of medically important events include intensive 
treatment in an emergency room or at h ome for allergic bronchospasm; blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059]; and development of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a medicall y important event and subject to expedited reporting 
requirements.
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis
) that 
require medical or surgical intervention or lead to IMP interruption, modifi cation, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogram, x- rays, vital signs) that are 
associated with signs and/or sy mptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections7.1.1and 7.1.2. If the laboratory  
abnormality is part of a sy ndrome, record the s yndrome or diagnosis (eg, anemia), not the 
laboratory  result (ie, decreased hemoglobin).
For specific information on handling of clinical laboratory  abnormalities in this study , please
refer to Section 7.5
.
7.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified sub
-investigator is responsible for assessing AEs and SAEs for 
causality and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified sub- investigator is responsible for assessing t he relationship to IMP
therapy using clinical judgment and the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the IMP. For SAEs, an 
alternative causality must be provided (eg, pre -existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by [CONTACT_10853].
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page51 08 April2016It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of adverse event reporting. 
The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study  procedure.
Yes:The adverse event occurred as a result of protocol procedures (eg,venipuncture)
7.2.2. Assessment of Severity
The severit y grading of AEs will be assessed as Grade 1, 2, 3 or 4 using the Common 
Terminology  Criteria for Adverse Events (CTCAE) version 4.03. For AEs associated with 
laboratory  abnormalities, the event should be graded on the basis of the clinical severit y in the 
context of the underly ing conditions; this may  or may not be in a greement with the grading of 
the laboratory abnormality . 
The only modification to the CTCAE criteria is the addition of a Grade 1 upper respi[INVESTIGATOR_696] , as 
described in 
Appendix 4.
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to [COMPANY_009]
7.3.1. Requirements for collection prior to study drug initiation:
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
should be reported on the eCRF: all SAEs and adverse events relate d to protocol -mandated 
procedures.
[IP_ADDRESS]. Adverse Events
Following initiation of study  medication, collect a ll AEs, regardless of cause or relationship, 
until [ADDRESS_867545] that certain AEs be followed bey ond the protocol defined follow up 
period.
[IP_ADDRESS]. Serious Adverse Events
All SAEs, regardless of cause or relationship, that occurs after the subject first consents to 
participate in the stud y (ie, signing the informed consent) and throughout the duration of the 
study, including the protocol -required post treatment follow-up period, must be reported to the 
eCRF database and [COMPANY_009] DSPH as instructed. This also includes any SAEs resulting from 
protocol-associated procedures performed after informed consent is signed.
GS-[ADDRESS_867546] dose of study  
drug, regardless of causality , should also be reported. 
Investigators are not obligated to activel y seek SAEs after the protocol defined follow up period; 
h
owever, if the investigator learns of an y SAEs that occur after stud y participation has concluded 
and the event is deemed relevant to the use of IMP, he/she should promptly  document and report 
the event to [COMPANY_009] DSPH.
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline .
[IP_ADDRESS]. Electronic Serious Adverse Event (eSAE) Reporting Process 
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to [COMPANY_009] DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instr uctions can be found in the eCRF completion guidelines.
If for any reason it is not possible to record the SAE information electronically , ie, the eCRF 
database is not functioning, record the SAE on the paper serious adverse event reporting 
form and submit within 24 hours to:
[COMPANY_009] DSPH Email: [EMAIL_201]
Fax: [PHONE_1882]-
522-5477
As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
If anSAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary.
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the
eCRF completion guideline. 
For fatal or life -threatening events, copi[INVESTIGATOR_3103], autops y reports, and other 
documents are alsoto be submitted by e-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability of a document to the subject identifiers.
Additional information may  be requested t o ensure the timely  completion of accurate safet y 
reports.
Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s eCRF and the event description section of the SAE form.
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page53 08 April20167.4. [COMPANY_009] Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials D irective (2001/20/EC) and relevant updates, and 
other country -specific legislation or regulations, 
[COMPANY_009] may  berequired to expedite to 
worldwide regulatory  agencies reports of SAEs, serious adverse drug reactions (SADRs) ,or 
S[LOCATION_003]Rs
.In accordance with th e EU Clinical Trials Directive (2001/20/EC), [COMPANY_009] or a 
specified designee will notify  worldwide regulatory  agenciesand the relevant IECin concerned 
Member States of applicable S[LOCATION_003]Rs as outlined in current regulations.
Assessment of e xpectedness forSAEs will be determined by  [CONTACT_10855] i nvestigator’s brochure or relevant local label as applicable. 
All investigators will receive a safet y letter notifying them of relevant S[LOCATION_003]R reports associated 
with any study IMP. The investigator should notify  the IRB/IEC of S[LOCATION_003]R reports as soon as is 
practical, where this is required by  [CONTACT_384766], and in accordance with the local 
institutional policy . 
7.5. Clinical Laboratory Abnormalities and Other Abno rmal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities are usuall y not recorded as AEs or SAEs. Howev er, laboratory  
abnormalities (e g, clinical chemistry , hematology , and urinal ysis) independent of the 
underlyingmedical cond ition that require medical or surgical intervention or lead to 
investigational medicinal product interruption or discontinuation must be recorded as an AE, as 
well as an SAE, if applicable. In addition, laboratory o r other abnormal assessments 
(eg,electrocardiogram, X -rays, vital signs) that are associated with signs and/or sy mptoms must 
be recorded as an AE or SAE if they  meet the definition of an AE (or SAE) as described in 
Sections7.3.1.1and7.3.1.2. If the laboratory  abnormality  is part of a s yndrome, record the 
syndrome or diagnosis (ie, anemia) not the laboratory  result (ie, decreased hemoglobin).
Severity should be recorded and graded according to the modified CTCAE Grading Scale as 
described in Appendix 4
. For AEsassociated with laboratory abnorm alities, the event should be 
graded on the basis of the clinical severity  in the context of the underly ing conditions; this ma y 
or maynot be in agreement with the grading of the laboratory  abnormality .
7.5.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event
Continue study  drug at the discretion of the investigator.
7.5.2. Grades 3 and 4 Laboratory Abnormality or Clinical Event
For a Grade 3 and 4 clinical event or clinicall y significant Grade 3 and 4 laboratory abnormality 
confirmed b y repeat testing ( preferably within 3 calendar day s after receipt of the original 
testresults), study drug should be permanentl y discontinued and the subject managed according 
to local practice. The subject should be followed as clinically  indicated until the laboratory  
abnormality  returns to baseline or is otherwise explained, whichever occurs first. A clinically  
GS-[ADDRESS_867547] labelling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Produ
ct complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.  
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page55 08 April20167.7.2. Instructions for Reporting Special Situations
[IP_ADDRESS]. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study medication and throughout the study , including the post study drug follow -
up 
period, to [COMPANY_009] DSPH using the pregnancy  report form within 24 hours of becoming aware of 
the pregnancy .
Refer to Section 7.3and the eCRF completion guidelines for full instructions on the mechanism 
of pregnancy  reporting.
The pregnancy itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premature termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported with
in [ADDRESS_867548] in formation is as follows: 
Email:[EMAIL_201] and Fax: +1 (650) [ADDRESS_867549] should 
continue until the conclusion of the pregnancy . If the end of the pregnancy  occurs after the study  
has been completed, the outcome should be reported directl y to [COMPANY_009] DSPH, fax 
number 
+[PHONE_2520] or email [EMAIL_201].
Refer to A ppendix5for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements
.
[IP_ADDRESS]. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to [COMPANY_009] DSPH within [ADDRESS_867550] of situations that involve study  IMPand/or [COMPANY_009] concomitant 
medications, but do not apply  to non-[COMPANY_009] concomitant medications. 
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page56 08 April2016Special situations involving non -[COMPANY_009] concomitant medications does not need to be reported on 
the special situations report form; however, for special situations that result in AEs due to a 
non-[COMPANY_009] concomitant medication, the AE should be reported on the AE form. 
Any inappropriate use of concomitant medications prohibited by  [CONTACT_10857] “misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer toSection3and the eCRF completion guidelines for full instructions on the mechanism of 
special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the sy mptoms and 
signs, clinical management, and outcome will be reported, when available.
GS-9876 
Protocol GS-US-379-1582 
[COMPANY_009] Sciences, Inc. 
8. STATISTICAL CONSIDERATIONS 
8.1. Analysis Objectives and Endpoints 
8.1.1. Analysis Objectives 
The primaty objective is: Original 
• To evaluate the effect of GS-987 6 versus placebo for the treatment of signs and symptoms of 
RA in subjects with active RA as measured by [CONTACT_647805]28 (CRP) at 
Week 12 
The secondaty objectives are: 
• To evaluate the safety and tolerability of GS-9876 in subjects with RA 
• To explore the effect of GS-9876 on other disease-specific outcomes in RA 
The exploratmy objectives are: 
IT 
I 
I 
8.1.2. Primary Endpoint 
The primaty endpoint is change from baseline in DAS28 (CRP) at Week 12. 
8.1.3. Secondary Endpoint 
The secondaty endpoints include: 
• The proportion of subjects who achieve ACR 20/50/70 at Week 12 
• Change from baseline in HAQ-DI score at Week 12 
8.1.4. Exploratory Endpoints 
[COMPANY_003] 
I 
I 
CONFIDENTIAL Page 57 08 April2016 
GS-9876 
Protocol GS-US-379-1582 
[COMPANY_009] Sciences, Inc. 
IT 
I 
I I 
8.2. 
8.2.1. 
[IP_ADDRESS]. Analysis Conventions 
Analysis Sets 
All Randomized Original 
The all randomized analysis set includes all subjects who are randomized in the study. This is the 
primary analysis set for by-subject listings. 
[IP_ADDRESS]. Efficacy 
The primary analysis set for efficacy analyses will be the Full Analysis Set (F AS), which 
includes all randomized subjects who received at least 1 dose of study drug. 
[IP_ADDRESS]. Safety 
The primary analysis set for safety analyses will be the Safety Analysis Set, which includes all 
subjects who received at least 1 dose of study drug. 
[IP_ADDRESS]. Pharmacokinetics 
[IP_ADDRESS].1. PK Substudy Analysis Set 
The primary analysis set for intensive PK analyses will be the PK substudy analysis set, which 
includes all subjects in the Safety Analysis Set who have enrolled into the PK substudy, and have 
intensive PK concentration data to provide interpretable results for the specific parameters of 
interest for the analyte under evaluation. 
[IP_ADDRESS].2. PK Analysis Set 
The primary analysis set for general PK analyses will be the PK analysis set, which includes all 
subjects in the Safety Analysis Set who have at least 1 non-missing PK concentration data for 
GS-9876 and/or its metabolite(s). 
8.3. Data Handling Conventions 
PK concentration values and PK parameter values below the limit of quantitation (BLQ) will be 
presented as "BLQ" in the data listings. BLQ values that occur prior to the first dose will be 
treated as 0, BLQ values at all other time points will be treated as 112 of the lower limit of 
quantitation (LLOQ). 
CONFIDENTIAL Page 58 08 April2016 
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page59 08 April2016Laboratory  data that are continuous in nature but are less than the lower limit of quantitation or 
above the upper limit of quantitation will be imputed to the value of the lower or upper limit 
minus or plus one significant digit, respectivel y (eg, if the result of a contin uous laboratory  test is 
< 20, a value of 19 will be assigned; if the result of a continuous laboratory test is < 20.0, a value 
of 19.9 will be assigned).
8.4. Demographic Data and Baseline Characteristics
Demographic and baseline characteristics will be summarized using standard descriptive 
methods including sample size, mean, SD, median, Q1, Q3, minimum, and maximum for 
continuous variables and frequency  and percentages for categorical variables.
Demographic data will include sex, race, ethnicity , and age.
Baseline characteristics will include DAS28(CRP), HAQ- DI, SDAI, and CDAI .
8.5. Efficacy Analysis
The primary  endpoint for the study  is change from baseline in DAS28 (CRP) at Week 12, which 
will be anal yzed using a mixed model repeated measures (MMRM) approach. The model may  
include the fixed effects of treatment, visit, treatment by  [CONTACT_23259], and baseline value.  
Subjects will be included as a random effect . 
Secondary  endpoints include proportion of subjects who achieve ACR20/50/70 at Week 12 and 
change from baseline in HAQ-D I score at Week 12. The ACR20/50/70 response rates between 
each of the 2 GS -9876treated groups and the placebo group will be compared using a stratified 
Cochran-Mantel-Haenszel ( CMH)Chi-square test adjusting for stratification factor in 
randomization.  The difference in response rates between treatment groups and the 
corresponding 95% confidence intervals will be presented. The difference in change from 
baseline in HAQ -DI between treatment groups will be analy zed using a simila r MMRM 
approach.
Sensitivity  analyses may be performed for the efficacy  assessment.
Details on efficacy  analyses will be described in the statistical anal ysis plan.
8.6. Safety Analysis
All safety analyses will be performed using the safety  analysis set.
Safetywill be evaluated by  [CONTACT_199618], phy sical examinations, vital 
signs measurements at various time points during the study , and by [CONTACT_123306].
All safety data collected on or after the first dose of study drug admi nistration up to [ADDRESS_867551]’s extent of exposure to study drugwill be generated from the s tudy drug
administration page of the eCRF. Exposure data will be summarized by  [CONTACT_1570].
Duration of exposure to study  drug will be expressed as the number of weeks between the first 
and last dose of the study drug, inclusive, regardless of tempora ry interruptions in study  drug 
administration and summarized by  [CONTACT_1570].
8.6.2. Adverse Events
Clinical and laboratory  adverse events will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Grou
p Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT),and Lower -Level Term (LLT) will be 
attached to the clinical database.
Treatment -emergent adverse events (TEAEs) are defined as one or both of the following:
Any AEswith an onset date on or after the stud y drug start date and no later than 30 days 
after permanent discontinuation of study  drug.
Any AEsleading to premature discontinuation of study  drug.
Summaries (number and percentage of subjects) of TEAEs b y SOC and PT will be provided. 
Treatment -emergent AEs will also be summarized by  [CONTACT_454190] . In 
addition, TEAEs leading to premature discontinuation of study  drug and study  will be 
summarized and listed.
8.6.3. Laboratory Evaluations
Selected laboratory  data will be summarized (n, mean, SD, median, Q1, Q3, minimum, and 
maximum) by  [CONTACT_1570]. Absolute values and 
change from baseline at all scheduled 
timepoints will be summarized.
Graded laboratory  abnormalities will be defined using CTCAE 4.03 grading scale( Appendix4)
.
Incidence of treatment -emergent laboratory  abnormalities, defined as values that increase at least
one toxicity  grade from baseline at an y time post baseline up to the date of last dose of study  
drug plus [ADDRESS_867552] or 
summarized by  [CONTACT_647811].
GS-9876 
Protocol GS-US-379-1582 
[COMPANY_009] Sciences, Inc. 
8.7. Pharmacokinetic Analysis Original 
Plasma concentrations of GS-9876 will be listed and smmnarized using descriptive statistics 
( eg, sample size, arithmetic mean, geometric mean, % coefficient of variation, standard 
deviation, median, minimum, and maximum). 
PD 
Plasma concentrations ofGS-9876 metabolite(s) and/or MTX may also be detennined and 
analyzed. 
8.8. Biomarker Analysis 
PD 
8.9. Data Monitoring Committee 
An extemal multidisciplinruy DMC will review the progress of the study and perf01m interim 
reviews of safety data in order to protect subject welfare and preserve study integrity. The DMC 
is to recommend to the sponsor whether the nature, frequency , and severity of adverse effects 
associated with treatment watTant the eru·ly termination of the study, whether the study should 
continue as planned, or the study should continue with modifications. 
DMC will review unblinded safety data. The initial DMC review will be conducted after the 
21st subject in the study has been treated for [ADDRESS_867553] of one dose of GS -9876 compared to 
placebo based on th e change from baseline in DAS28 (CRP) at Week 12. When assuming a 
difference of 1.[ADDRESS_867554] deviation of 1.35, 20 subjects 
in each of the GS -9876 groups and 20 in the placebo group are required to obtain 78 percent 
power at a 2-sided 0.05- level. Therefore, the total sample size will be 60 (20 per treatment 
group).
GS-[ADDRESS_867555] es of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, and 
SouthAfrica), International Conference on Harmonisation (I CH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichev er affords the greater 
protection to the study  subject. These standards are consistent with the EUClinical Trials 
Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 Code of Federal Regulations (CFR) 312, subpart D, “Responsibilities of Sponsors 
and Investigators,” [ADDRESS_867556] be provided prior to 
the investigator’s (and any  sub-investigator’s) participation in the study . The investigator and 
sub-investigator agree to notify  [COMPANY_009] of an y change in reportable interests during the stud y and 
for [ADDRESS_867557] (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed cons ent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to an IRB/IEC.The investigator will not begin an y study subject activi ties 
until approval from the IRB/IEC has been documented and provided as a letter to the 
investigator.
Before implementation, the investigator will submit to and receive documented approval from 
the IRB/IECany modifications made to the protocol or any acc ompanying material to be 
provided to the subject after initial I RB/IEC approval , with the exception of those necessary  to 
reduce immediate risk to study  subjects.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking an y study-related procedures. The 
GS-[ADDRESS_867558] currentIRB/IECapproved consent form for documenting written 
informed consent. Each informed consent (or assent as applicable) will be appropriatel y signed 
and dated b y the subject or the subject’s legally authorized representative and the person 
conducting the consent discussion, a nd also by  [CONTACT_550252]/IEC or
local requirements. The consent form will inform subjects about pharmacogenomics testing and 
sample retention, and their right to receive clinically  relevant pharmacogenomics analy sis 
results.
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only  subject initials, date of birth, another 
unique identifier (as allowed b y local law) ,and an identification code will be recorded on an y 
form or biological sample submitted to the Sponsor, IRB
/IEC,or laboratory . Laboratory  
specimens must be labeled in such a way as to protect subject identity  while allowing the results 
to be recorded to th e proper subject. Refer to specific laboratory  instructions. NOTE :The 
investigator must keep a screening log showing codes, names, and addresses for all subjects 
screened and for all subjects enrolled in the trial. Subject data will be processed in accord ance 
with all applicable regulations. 
The investigator agrees that all information received from [COMPANY_009], including but not limited to the 
investigator brochure, this protocol, eCRF , the IMP, and any other study  information, remain the 
sole and exclusive p roperty of [COMPANY_009] during the conduct of the study  and thereafter. This 
information is not to be disclosed to any  third party  (except employ ees or agents directl y 
involved in the conduct of the study  or as required by  [CONTACT_2371]) without prior written consent from
[COMPANY_009]. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator m ust maintain adequate and accurate records to enable the conduct of the study  
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1)investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, eCRF and query  forms, IRB 
/IEC and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and aut horization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identification (name, date of birth, gender);
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page65 08 April2016Documentati on that subject meets eligibility  criteria, ie, history , physical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
Documentation of the reason(s) a consented subject is not enrolled
Participation in study (including study number);
Study discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results of efficacy  parameters, as required b y the protocol;
Start and end date (including dose reg imen) of IMP, including dates of dispensing and return;
Record of all adverse events and other safety  parameters (start and end date, and including 
causality and severity);
Concomitant medication (including start and end date, dose if relevant; dose change s);
Date of study completion and reason for earl y discontinuation, if it occurs.
All clinical study  documents must be retained b y the investigator until at least [ADDRESS_867559] approval of a marketing application in 
an ICH region (ie, [LOCATION_002], Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until [ADDRESS_867560] been received.  Subsequent to data entry , a study monitor will perform 
source data verification within the 
electronic data capture ( EDC)system.Original entries as well 
as any changes to data fields will be stored in the audit trail of the system.  Prior to dat abase lock 
(or any interim time points as described in the clinical data management plan), the investigator 
will use his/her log in credentials to confirm that the forms have been reviewed, and that the 
entries accurately  reflect the information in the source documents. The eCRF capture sthe data 
required per the protocol schedule of events and procedures. System-generated or manual 
queries will be issued to the investigative site staff as data discrepancies are identified by  [CONTACT_550253], who routinel y review the data for completeness, correctness, and 
consistency . The site coordinator is responsible for responding to th e queries in a timely  manner, 
within the sy stem, either by  [CONTACT_204983] , and 
providing the reason for the update (eg, data entry  error).At the conclusion of the trial, [COMPANY_009] 
will provide the site with a r ead-only archive cop y of the data entered b y that site. This archive 
must be stored in accordance with the records retention requirements outlined in Section 9.1.5.
9.1.7. Investigational Medicinal Product Accountability and Return
Where possible, IMP should be destroyed at the site. At the start of the study, the study monitor 
will evaluate each stud y center’s IMPdisposal procedures and provide appropriate instruction for 
disposal or return of unused IMPsupplies. If the site has an appropriate standard o
perating 
procedure (SOP) for drug destruction as determined by  [CONTACT_10869] , the site may  destroy 
used (empt yor partially  empty) and unused IMPsupplies as long as performed in accordance 
with the site’s SOP. This can occur onl y afterthe study monitor has performed drug 
accountability  during an on -site monitoring visit . 
A copy of the site’s IMP Disposal SOP or written procedure (signed and dated by  [CONTACT_978] 
[INVESTIGATOR_204944]) will be obtained for [COMPANY_009] site files. If the site does not have acceptable 
procedures inplace, arrangements will be made between the siteand [COMPANY_009] Sciences 
(or[COMPANY_009]Sciences’ representative) for return of unused study  drug supplies. 
If IMPis destroyed on site, the investigator must maintain accurate records for all IMPs
destroyed. Upon study completion, copi[INVESTIGATOR_647795]. Another cop y will be returned to [COMPANY_009].
The study  monitor will review IMP supplies and associated records at periodic intervals.
9.1.8. Inspections
The investigator will make available all source documents and other records for this trial to 
[COMPANY_009]’s appointed stud y monitors, to I RBs or IECs, or to regulatory  authority  or health authorit y 
inspectors.
GS-[ADDRESS_867561] submit a ll protocol modifications to the IRB/IEC in 
accordance with local requirements and receive 
documented IRB /IEC approval before 
modifications can be implemented.
9.2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to applicable regulatory  agencies.
[COMPANY_009] will ensure that the report meets the standards set out in the I CH Guideline for Structure 
and Content of Clinical Study  Reports (I CHE3). Note that an abbreviated report may  be 
prepared in ce rtain cases.
Investigators in this study  may communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met:
The results of the stud y in their entiret y have been publicly disclosed by [CONTACT_647812], manuscript, or presentation form or the stud y has been completed at all 
study sites for at least [ADDRESS_867562] 30 day s before submission of the 
publication or presentation. 
No such communication, presentation, or publication will include [COMPANY_009]’s confidential 
information (see Section 9.1.4).
The investigator will comply  with [COMPANY_009]’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obt
ain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services pe rformed under this 
protocol, eg, attendance at I nvestigator's Meetings.  If requ ired under the applicable statutory  and 
regulatory  requirements, [COMPANY_009] will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursement
s, consulting fees, and any  other transfer of value.
GS-[ADDRESS_867563] access to the 
investigator’s source documentation in order to verify  the accuracy ofthe data recorded in the 
eCRF.
The monitor is responsible for routine review of the eCRFat regular intervals throughout the 
study to verify adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The m onitor should have access to an y subject records needed to 
verify the entries on the eCRF . The investigator agrees to cooperate with the monitor to ensure 
that any problems detected 
through an y type ofmonitoring (central, on site) are resolved.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of [COMPANY_009] may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to no tify the [COMPANY_009] medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency or [COMPANY_009] access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at any time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authority(ies), IRBs, and IECs. In terminating the study, [COMPANY_009] and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.
GS-[ADDRESS_867564], et al. 2010 
Rheumatoid ar thritis classification criteria: an American College of 
Rheumatology /European L eague Against Rheumatism collaborative initiative. 
Arthritis Rheum 2010;62 (9):2569-81.
Arthritis Foundation. Rheumatoid Arthritis Fact Sheet.  2008.
Braselmann S, Tay lor V, Zha o H, Wang S, Sy lvain C, Baluom M, et al. R406, an orall y available 
spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune 
complex-mediated inflammation. J Pharmacol Exp Ther 2006;319 (3):998 -1008.
Cha HS, Bo yle DL, Inoue T, Schoot R, Tak PP, Pi[INVESTIGATOR_050] P, et al. A novel spleen ty rosine kinase 
inhibitor blocks c -Jun N-terminal kinase -mediated gene expression in 
synoviocytes. J Pharmacol Exp Ther 2006;317 (2):571 -8.
Coffey G, DeGuzman F, Inagaki M, Pak Y, Delaney  SM, Ives D, et al. Specifi
c inhibition of 
spleen tyrosine kinase suppresses leukocy te immune function and inflammation in 
animal models of rheumatoid arthritis. J Pharmacol Exp Ther 2012;340 (2):[ADDRESS_867565] D, Goldsmith C, et al. Amer ican College 
of Rheumatology . Preliminary  definition of improvement in rheumatoid arthritis. 
Arthritis Rheum 1995;38 (6):727-35.
Helmick CG, Felson DT, L awrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the 
prevalence of arthritis and other rhe umatic conditions in the [LOCATION_002]. Part I . 
Arthritis Rheum 2008;58 (1):15-25.
Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B 
cells after depletion with rituximab in patients with rheumatoid arthritis. Arthriti s 
Rheum 2006;54 (2):613-20.
Liao C, Hsu J, Kim Y, Hu DQ, Xu D, Zhang J, et al. Selective inhibition of spleen tyrosine 
kinase (SYK) with a novel orally  bioavailable small molecule inhibitor, RO9021, 
impi[INVESTIGATOR_647796]: implications for SYK 
inhibitors in autoimmune disease therap y. Arthritis research & therap y 2013;15 
(5):R146.
Martin F, Chan AC. B cell immunobiology  in disease: evolving concepts from the clinic. Annu 
Rev Immunol 2006;24:[ADDRESS_867566] clinical trial results with antitumor necrosis factor and 
nonantitumor necrosis factor biologics for rheumatoid arthritis. Current opi[INVESTIGATOR_433389]  2013;25 (3):384 -90.
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page70 08 April2016Pi[INVESTIGATOR_386029], Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, et al. I nflammation and bone 
erosion are suppressed in models of rheumatoid arthritis following treatment with 
a novel Sy k inhibitor. Clin I mmunol 2007;124 (3):244 -57.
Prevoo ML , van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL . 
Modified disea se activity scores that include twenty -eight-joint counts. 
Development and validation in a prospective longitudinal study  of patients with 
rheumatoid arthritis. Arthritis Rheum 1995;38 (1):44-
8.
Shlomchik MJ. Sites and stages of autoreactive B cell activation and regulation. I mmunity 
2008;28 (1):18 -28.
Song YW, Kang EH. Autoantibodies in rheumatoid arthritis: rheumatoid factors and 
anticitrullinated protein antibodies. QJM 2010;103 (3):139-46.
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page71 08 April201611. APPENDICES
Appendix 1.Investigator Signature [CONTACT_10882] 2.Study Procedures Tables
Appendix 3.Laboratory Assessments Table
Appendix 4.Common Terminology Criteria for Adverse Events (CTCAE) v4.03
Appendix 5.Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
Appendix 6.The2010 American College of Rheumatology –European League Against 
Rheumatism Collaborative Initiative Classification Criteria for Rheumatoid 
Arthritis {Aletaha et al 2010}
Appendix 7.American College of Rheumatology Response Evaluations/ Preliminary Definition 
of Improvement in Rheumatoid Arthritis {Felson et al 1995}
Appendix 8.Disease Activity Score for 28 Joint Count (DAS28) {Prevoo et al
 1995}
Appendix 9.Procedures and Specifications
GS-9876 
Protocol GS-US-379-1582 
[COMPANY_009] Sciences, Inc. 
Appendix 1. Original 
Investigator Signature [CONTACT_54678], INC. 
STUDY ACKNOWLEDGEMENT 
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Proof-of-Concept Study to 
Evaluate Safety, Tolerability, and Efficacy of GS-9876 in Subjects with Active Rheumatoid 
Arthritis on Background Therapy with Methotrexate 
GS-US-379 -1582, Original Protocol, 08 April2016 
~!sa~;~:~ has been approved by [CONTACT_647813] ~punc_Ilpl~folJ.ou tDina Ri.QU::tture documents 
Franziska Matzkies , MD 
Medical Monitor Name (Printed) 
~plr,Q -Ill -2iJ I c 
Date 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copi[INVESTIGATOR_10805], Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator [CONTACT_5627] (Printed) Signature 
[CONTACT_279395] [ADDRESS_867567]-
Treatment 
Week2 Week4 WeekS Week12 ETb Follow-Up< 
±3 ±3 ±3 ±3 ±3 ±5 
X X X X X X 
X X X X X X 
X X X X X X 
X X X X X X X X X X X 
X X X X X X 
X X X X X X 
X X X 
X X X X 
X X X X X 
08 April 2016 
GS-9876 
Protocol GS-US-379-1582 
[COMPANY_009] Sciences, Inc. 
Visit Screeninga Dayl Week2 Week4 Week8 
Window in Days -28 ±3 ±3 ±3 
RF /CCP h, i, i X 
h .. IgA, IgG, and IgM ''· J X - ~ X 
PK SamplesP X X X - rr X 
Study Drug Dispensation X X X 
Study Drug Administration (In-Clinic) r X X X X 
Adverse Events' Continuous 
Concomitant Medications [ADDRESS_867568] dose of study drug. 
b Early Termination assessments should be performed within 72 hours of early termination from the study. 
c 28 (±5) days after the last administration of study drug, all subjects will return for an in-clinic follow-up visit. Week12 
±[ADDRESS_867569]-
Treatment 
ETb Follow-Upc 
±3 ±[ADDRESS_867570] reports no change in symptoms, then noPE is necessary. 
f Vital signs include resting blood pressure, pulse, respi[INVESTIGATOR_1487], temperature (obtained orally), height and weight. Height and weight will be collected at Screening only. 
g Conduct Day 1 ECG predose (prior to study drug administration). 
h At Day 1 and Week 12 visits, the HAQ-DI, Patient's Assessment of Pain, and Patient's Global Assessment of Disease Activity are recommended to be done prior to the [ADDRESS_867571] 
will also be collected. 
Samples will be collected at Day 1, Week 4, and Week 12 or ET visits for exploratory disease and/or pathway markers relevant to rheumatoid arthritis. Sampling timepoints 
and assessments may be modified during the study based on assay availability and/or emerging data. 
m As needed per exclusion criteria (refer to Section 4.3) 
n Disease-specific questionnaires and activity scales include the HAQ-DI, Patient's Assessment of Pain, Patient's Global Assessment of Disease Activity, and Physician's 
Global Assessment of Disease Activi!Y:..;.·----------------------------------. 
0 I PD 
CONFIDENTIAL Page 74 08 April 2016 
GS-9876 
Protocol GS-US-379-1582 
[COMPANY_009] Sciences, Inc. Original 
p PK samples will be collected prior to study drug administration (pre·-dose at Weeks 2, 8, and [ADDRESS_867572] dose. 
q [COMPANY_003] 
r On Day 1, study diug adnumstrat iOii'"(iil-Clilli.Cj"ShOUi d betile"Iast study procedw·e pet'lonue d. On Week 4, study dmg administJ·ation (in-clinic) should be the first study 
procedtu-e perfom1ed (with the exception of predose PK for[[COMPANY_003] I subjects only). At all other tJ·eatJuent visits, study drug administJ·ation should occur after 
predose assessments are completed. 
s After infonued consent, but prior to initiation of study medication, all SAEs and adverse events related to protocol-mandated procedw·es shall be collected . Following 
initiation of study medication, all SAEs and all AEs, regardless of cause or relationship , shall be collected . Refer to Section 7.3 for more detail. 
At Screening , all medication taken up to 30 days prior to the Screening visit will be recorded on the eCRF. 
CONFIDENTIAL Page 75 08 April2016 
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page76 08 April 2016Appendix 3. Laboratory Assessment sTable
Hematology Chemistry Urinalysis Other
Hematocrit
Hemoglobin
Platelet count
Red blood cell (RBC) 
count
White blood cell (WBC) 
count
Differentials (absolute 
and percentage), 
including:
Leukocyte s
Monocytes
Neutrophils
Eosinophils
Basophils
Reticulyte count
Mean corpuscular 
volume (MCV)Alkaline phosphatase
Aspartate aminotransferase
(AST)
Alanine aminotransferase
(ALT)
Total bilirubin
Direct and indirect 
bilirubin
Total protein
Albumin
Bicarbonate
Blood urea nitrogen 
(BUN)
Calcium
Chloride
Serum creatinine
Glucose
Phosphorus
Magnesium
Potassium
Sodium
Amylase
Lipase Appearance
Blood
Color
Glucose
Leukocyte esterase
pH
Protein
Urobilino gen
Reflex to microscopic 
urinalysis if dipstick result 
is abnormal.Urine drug screenfor:
Amphetamines
Cocaine
Methadone
Opi[INVESTIGATOR_647797], IgG, IgM
C-reactive protein ( CRP)
Rheumatoid factor and cyclic 
citrullinated peptide (RF/CCP)
Quantiferon (if required per 
exclusion criteria)
CD19 (if required per 
exclusion criteria)
RNA
Coagulation Serology Pregnancy
Activated partial 
thromboplastin time 
(aPTT)
Prothrombin time (PT)
International normalized 
ratio (INR)Hepatitis BsAg and core 
Ab 
Hepatitis C Ab
HIVIn females of childbearing 
potential:
Serum β-hCG (Screening and 
if positive urine β-hCG)
Urine β-hCG (allother visits)
Ab = antibody
β-hCG = beta-human chorionic gonadotropin
BsAg = B surface antigen
IgA, IgG, IgM = immunoglobulins A, G, M
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page77 08 April 2016Appendix 4. Common Terminology Criteria for Adverse Events (CTCAE) v4.03
CTCAE v4.03 can be accessed from the below link:
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06- 14_QuickReference_8.5x11.pdf
The only modification to the CTCAE criteria is the addition of a Grade 1 upper respi[INVESTIGATOR_204946]:
CTCAE 
v4.0 Term Grade 1
Grade 2 Grade 3
Grade 4 Grade5CTCAE v4.03 
AE Term 
Definition
Upper 
respi[INVESTIGATOR_204947]; 
symptomatic 
relief (eg, 
cough 
suppressant, 
decongestant)Moderate 
symptoms; 
oral 
intervention 
indicated 
(eg,antibiotic, 
antifungal, 
antiviral)IV antibiotic, 
antifungal, or 
antiviral 
intervention 
indicated; 
radiologic, 
endoscopic, or 
operative 
intervention 
indicatedLife-
threatening 
consequences; 
urgent 
intervention 
indicatedDeath A disorder 
characterized by 
[CONTACT_204985][INVESTIGATOR_4352] 
(nose,paranasal 
sinuses, pharynx, 
larynx, or 
trachea).
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page78 08 April 2016Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Definitions
a)Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or with medically  documente d ovarian failure.  
Women are considered to be in a postmenopausal state when they  are >54years of age with 
cessation of previously  occurring menses for > [ADDRESS_867573] of an y age.
b)Definition of Male Fertility
For the purposes of this study , a male born subject is considered fertile after the initiation of 
puberty unless permanently  sterile by [CONTACT_647814].
2)Contraception Requirements for Female Subjects
a)Study Drug Effects on P regnancy and Hormonal C ontraception
GS-9876is contraindicated in pregnancy  as its teratogenicity /fetotoxicity  profile is unknown. 
GS-[ADDRESS_867574] version of the investigator’s brochure for additional information.
b)Contraceptive Methods Permitted for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires the u se of highly effective
contraceptive measures.  Women must also not rely on hormone- containing contraceptives as a 
form of birth control during the stud y, though they may  continue hormonal contraception if they  
prefer to do so.  Women must have a negative serum pregnancy  test at Screening and a negative 
pregnancy  test on the Day
 [ADDRESS_867575] dose of study  drug.  Pregnancy  tests will be 
performed as defined b y the schedule of assessments ( Appendix 2).
Female subjects of childbearing potential mustagree to one of the following from Screening 
until [ADDRESS_867576] dose of stud y drug.
Complete abstinence from intercourse of reproductive potential.  Abstinence is an acceptable 
method of contraception only  when it is in line with the subject ’s preferred and usual 
lifestyle.
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page79 08 April 2016Or
Consistent and correct use of 1 of the following methods of birth control listed below. 
Intrauterine device (IUD) with a failure rate of <1% per year
Tubal sterilization
Essure micro- insert system (provided confirmation of success 3 months after procedure)
Vasectom y in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least [ADDRESS_867577] dose of study  drug.
3) Contraception Requirements for Male Subjects
It is theoreticall y possible that a relevant s ystemic concentration may  be achieved in a female 
partner from exposure of the male subject’s seminal fluid.  Therefore, male subjects with female 
partners of childbearing potential must use condoms during treatment and until [ADDRESS_867578] dose of study  drug
4) Unacceptable Birth Control Methods
Birth control methods that are unacceptableinclude periodic abstinence (e g, calendar, ovulation, 
symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides onl y, and 
lactational amenorrhea method (LAM).  Female condom and male condom should no t be used 
together.
5) Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study, or if they  become pregnant within [ADDRESS_867579] report the information to 
the investigator.  Instructions for reporting pregnancy , partner pregnancy , and pregnancy  
outcome are outlined in Section [IP_ADDRESS].
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page80 08 April 2016Appendix 6. The 2010 American College of Rheumatology –European League
Against Rheumatism Collaborative Initiative Classification Criteria 
for Rheumatoid Arthritis {Aletaha et al 2010}
Target population (Who should be tested?): Patients who have at least 1 joint with 
definite clinical synovitis (swelling)a with the synovitis not better explained by 
[CONTACT_204987] (score -based algorithm : add score of categories A -D;
a score of ≥6/10 is needed for classification of a patient as having definite RA)c
A. Joint involvementd
1 large jointe0
2-10 large joints 1
1-3 small joints (w ith or without involvement of large joints)f2
4-10 small joints (with or w ithout involvement of large joints) 3
>10 joints (at least 1 small joint)g5
B. Serology (at least [ADDRESS_867580] result is needed for classification)h
Negative RF andnegative ACPA 0
Low-positive RF orlow-positive ACPA 2
High-positive RF orhigh-positive ACPA 3
C. Acute-phase reactants (at least [ADDRESS_867581] result is needed for classification)i
Normal CRP andnormal ESR 0
Abnormal CRP or abnormal ESR 1
D. Duration of symptomsj
<6weeks 0
≥6 weeks 1
aThe criteria are aimed at classification of newly presenting patients. In addition, patients with erosive disease typi[INVESTIGATOR_204949] (RA) with a history compatible with prior fulfillment of the 2010 criteria should be classified as having 
RA. Patients with longstanding disease, including those whose disease is inactive (with or without treatment) who, based on 
retrospectively available data, have previously fulfilled the [ADDRESS_867582] should be consulted.
cAlthough patients with a score of <6/[ADDRESS_867583] category possible based on the pattern of joint involvement.
e "Large joints" refers to shoulders, elbows, hips, knees, and ankles.
f"Small joints" refers to the metacarpophalangeal joints, proximal interphalangeal join ts, second through 
fifthmetatarsophalangeal joints, thumb interphalangeal joints, and wrists.
gIn this category, at least [ADDRESS_867584] be a small joint; the other joints can includ e any combination of large 
and additional small joints, as well as other joints not specifically listed elsewhere (eg, temporomandibular, 
acromioclavicular, sternoclavicular).
GS-[ADDRESS_867585] fo r the laboratory and assay; low -positive refers to IU 
values that are higher than the ULN but ≤[ADDRESS_867586] for the laboratory and assay; high -positive refers to IU values that 
are >[ADDRESS_867587] for the laboratory and assay. Where rheumatoid factor (RF) info rmation is only available as positive 
or negative, a positive result should be scored as l ow-positive for RF. ACPA =anti-citrullinated protein antibody.
i Normal/abnormal is determined by [CONTACT_51091]. CRP = C-reactive protein; ESR = erythro cyte sedimentation 
rate.
jDuration of symptoms refers to patient self -
report of the duration of signs or symptoms of synovitis (eg, pain, swelling, 
tenderness) of joints that are clinically involved at the time of assessment, regardless of treatment statu s.
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page82 08 April 2016Appendix 7. American College of Rheumatology Response Evaluations/ 
Preliminary Definition of Improvement in Rheumatoid Arthritis 
{Felson et al 1995 }
ACR 20/50/70Requires ≥ 20% /50%/70% improvement in tender joint count , AND
≥20%/50%/70% 
improvement in swollen joint count , AND
≥20%/50%/70% improvement in at least 3 ofthe following 5:
Patient’sAssessment of Pain
Patient’sGlobal Assessment of Disease Activity
Physician’sGlobal Assessment of Disease Activity
Patient’sassessment of phy sical  function (HAQ-DI)
Acute-phase reactant (CRP)
The following lists the disease activity measure followed by [CONTACT_454192]
1.Tender joint count
ACR tender joint count is an assessment of 68. The joint count should be done by  [CONTACT_204989], as assessed b y pressure and joint manipulation on physical 
examination. The information on various ty pes of tenderness should then be collapsed into a 
single tender -versus-nontender dichotom y.
2.Swollen joint count
ACR swollen joint count is an assessment of 66. Joints are classified as either swollen o r not 
swollen.
3.Patient’s A ssessment of P ain
A horizontal visual analog scale (VAS) will be used to assess the patient’s current level of pain.[ADDRESS_867588] week? Place a mark on the 
line below to indicate how severe your pain has been: 
No Pain Unbearable Pain
                                                
4Visual analog scales provided in this protocol are not to scale and should not be utilized for assessments.
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page83 08 April [ZIP_CODE].Patient’s Global Assessment of Disease Activity
A horizontal VASwill be used to provide the patient’s overall assessment of how the arthritis is 
doing.
Place a mark on the line below to indicate how you assess your current arthritis disease 
activity:
No arthritis activity Extremely active arthritis
5.Physician’s Global Assessment of Disease Activity
A horizontal VAS will be used to measure the physician’s assessment of the patient’s current 
disease activity .
Place a mark on the line below to indicate disease activity  (independent of the subject’s 
self-assessment) :
No Disease Activity Maximum Disease Activity
6.Patient’s A ssessment of P hysical Function
The HAQ
-DI will be used to provide a patient’s self -assessment of phy sical function.
7.Acute-phase reactant value
C-reactive protein level
GS-9876
Protocol GS -US-379-1582
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page84 08 April 2016Appendix 8. Disease Activity Score for 28 Joint Count (DAS28) {Prevoo et al 1995 }
Assessments of RA in patients by  [CONTACT_204990] (modified to include the 28 joint 
counts according to Smolen *1995) will be conducted at the measured time points. The DAS28 
consists of a composite score of the following variables: tender joint count, swollen joint count, 
CRP, and 
Patient’sGlobal Assessment of Disease Activityscore. The following equation will be 
used to calculate the DAS28 (CRP)
DAS28(CRP)0.56 √TJC280.28√SJC280.36ln(CRP 1) 0.014×(Patient’s Global 
Assessment of Disease Activity ) 0.96
TJC28 = number of joints tender out of 28
SJC28 = number of joints swollen out of 28
CRP = C-reactive protein
Patient’s Global Assessment of Disease Activity on a [ADDRESS_867589] include source documentation of general appearance, and 
the following bod y systems: Head, neck and thy roid; eyes, ears, nose, throat, mouth and tongue; 
chest (excluding breasts); respi[INVESTIGATOR_696] ; cardiovascular; ly mph nodes, abdomen; skin, hair, nails; 
musculoskeletal; neurological (must be performed at Screening) . 
Vital Signs
Assessment of vital signs will include measurement of resting blood pressure, pulse, respi[INVESTIGATOR_2865], and temperature. Body weight and height will also be included at Screening onl y.
Blood pressure will be measured us ing the following standardized process:
Subject should sit for  5 minutes with feet flat on the floor and measurement arm supported 
so that the midpoint of the manometer cuff is at heart level;
Use a mercury  sphygmomanometer or automatic blood pressure de vice with an appropriately  
sized cuff with the bladder centered over the brachial artery ;
Measure and record the blood pressure to the nearest [ADDRESS_867590] in a supi[INVESTIGATOR_19636] 5minutes prior to making a recording.
The investigator (or qualified designee) should review the ECG traces recorded in real time for 
clinically significant abnormalities.  On treatment ECGs should be compared to the subject’s 
Baseline as part of routine safet y monitoring.  
Fredericia Formula (QTcF)
QTc = QT/(RR^0.33) 
Health Assessment Questionnaire –Disability 
Index
The HAQ -DI is a patient reported questionnaire specific for RA.  It consists of 20 questions 
referring to 8component sets:  dressing/grooming, arising, eating, walking, hy giene, reach, gri p, 
and activities.  
Physician’s and Patient’s Global Assessment o f Disease Activity and Patient’s Global 
Assessment of Pain
The physician’s and the patient’s global assessment of disease activity  will be recorded on a 
100-mm horizontal VAS that ranges from “none” (0 mm, symptom free and no RA sy mptoms) 
to “maximum” (100 mm, 
maximum RA activity ).  The patient’s global assessment of pain will 
be recorded on a 100 -mm horizontal VAS that ranges from “none” (0mm)to “unbearable” 
(100mm).
GS-[ADDRESS_867591] particularl y duringthe blinded phase of the study .